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Abstract  
Reactivation of the multi-subunit ribonucleoprotein telomerase is the primary 
telomere maintenance mechanism in cancer, but it is rate-limited by the enzymatic 
component, telomerase reverse transcriptase (TERT). While regulatory in nature, TERT 
alternative splice variant/isoform regulation and functions are not fully elucidated and are 
further complicated by their highly diverse expression. In this thesis, I characterized TERT 
expression across normal and neoplastic tissues using TCGA and GTEx RNA-sequencing 
data. In doing so, I demonstrated the global overexpression and splicing shift towards full-
length TERT in neoplastic tissue. Furthermore, my studies identified tumour subtype 
expression differences possibly regulated by subtype-specific characteristics, detailed 
heterogeneity in both isoform function and prognostic potential and determined cancer cell 
lines with representative tumour specific TERT transcriptomes. Taken together, my work 
reinforced the need for tissue specific TERT investigations, provided avenues to do so, and 
brought to light the current technical limitations of bioinformatically analyzing TERT 
isoform expression. 
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Lay Summary 
When human cells divide, they replicate their DNA. However, the method used is 
imperfect and slightly shortens the DNA ends during each replication. To protect important 
genes, the ends are filled with repeated sequences called telomeres. While telomeres can 
increase the number of possible healthy replications, they also shorten with each cell 
division. Most adult cells with critically short telomeres will stop replicating and die off. 
However, more important cell types that replicate often, like stem cells, avoid cell death by 
re-lengthening their telomeres using the protein complex telomerase. The motor behind 
telomerase activity is telomerase reverse transcriptase (TERT). Unfortunately, cancer cells 
hijack this mechanism to continue dividing indefinitely. One possible way this is done is 
by changing the alternative splicing of the TERT. Normally, when genes are expressed the 
transcripts are cut and pasted (alternatively spliced) into different orientations, called 
isoforms. Some isoforms have the expected gene function, while others have new functions 
or no function. Adult cells express TERT, but mostly alternatively spliced non-functional 
isoforms. Therefore, cancer cells may change splicing back towards the functional isoform, 
amongst increasing overall expression. Complicating matters, the splicing and functions of 
some isoforms seem to differ between tissue types. In order to investigate this, I compared 
the expression of TERT isoforms in 33 cancer and 19 normal tissue types. In doing so, I 
confirmed that cancer cells typically increase overall TERT expression and shift splicing 
towards the functional isoform, whereas normal cells shift splicing towards non-functional 
isoforms. In addition, I identified normal tissue types with uncharacteristically increased 
TERT expression, indicating the possibility of another important function outside of 
telomere re-lengthening. As well, I identified cancer-specific subtypes with different 
expression patterns and outlined possible reasons as to why this may occur based on their 
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subtype characteristics. Finally, to potentially guide future investigations, I matched 
tumours with the most representative cancer cell lines based on TERT isoform expression 
patterns. Taken together, my work set the groundwork for and reinforced the need for 
tissue-specific investigations, provided avenues to do so, and brought to light the current 
limitations of bioinformatically analyzing TERT isoform expression.  
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Chapter 1 - Introduction 
1.1. Consequences of genomic structural linearity 
Eukaryotic genomes, such as human, are organized in linear chromosomes. This 
linearity poses two major problems related to DNA repair and replication. First, the 
terminal ends can be recognized as double-stranded breaks (DSB) leading to dicentric 
chromosomes from chromosomal fusions. Under optimal conditions, DSBs can be 
repaired through homologous recombination but this requires at least 100 base pairs of 
homology and occurs primarily during the synthetic phase of cellular replication (Sonoda 
et al., 2006). Without homologous regions the terminal chromosomal ends are fused 
using non-homologous end joining (NHEJ) (Sonoda et al., 2006). Continued cell 
divisions result in genomic instability during anaphase through cycles of DSBs and 
NHEJ; coined the breakage-fusion-bridge cycle (McClintock, 1941) (Figure 1a.) 
Secondly, DNA replication is semi-conservative (Meselson & Stahl, 1958), 
meaning each daughter cell has one parental DNA strand and one newly synthesized 
strand. During the DNA replication process the terminal 3’ end remains un-replicated due 
to the inability of DNA polymerases to elongate without an RNA primer or in the 3’ to 5’ 
direction. Therefore, continuous replication results in progressive DNA shortening, called 
the “end-replication problem” (Olovnikov, 1973) (Figure 1c). Both these problems are 
mitigated by telomeres and their associated structures.  
 
1.2. Telomere structure and function  
The ends of linear human chromosomes are capped with 5 to 15 kilobases (kb) 
(Samassekou et al., 2010) of tandemly repeated hexameric sequences (TTAGGG). 
Collectively, these repeats and associated proteins form a nucleoprotein complex called 
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telomeres (Olovnikov, 1973; Levy et al., 1992). The 3’ G-rich end of telomeres consist of 
a single-stranded overhang that spans about 200 nucleotides and is essential to telomere 
function (Wright et al., 1997). To protect against DSB detection, the G-rich overhang 
folds upon itself and displaces a penultimate portion of the double stranded telomeric 
region to form a telomere loop (T-loop) (Griffith et al., 1999). This loop is maintained 
and protected by its association with shelterin, a six-protein complex (de Lange, 2005). 
The telomere repeat binding factors 1 and 2 (TRF1 and TRF2) bind TTAGGG repeats at 
the double-stranded region. The protection of telomeres 1 (POT1) binds the single-
stranded TTAGGG repeats within the T-loop (de Lange, 2005). These three shelterin 
proteins (TRF1, TRF2, POT1) enable telomere binding specificity. The remaining three 
subunits: repressor/activator protein 1 (RAP1), tripeptidyl peptidase 1 (TPP1) and 
TRF1/TRF2 interacting nuclear protein 2 (TIN2), improve localization, stability and 
interconnectivity between the single- and double- stranded DNA binding subunits (Palm 
& de Lange, 2008). Thus, shelterin can mask chromosome ends and avoid unwarranted 
DSB repair to maintain genomic integrity (Figure 1b).  
In harmony with preventing a needless DNA damage response, telomeres also 
serve as guardians for detecting and responding to DNA damaging events. The high 
guanine content of telomeres leaves them highly susceptible to mutation (Rochette & 
Brash, 2010; Wang et al., 2010b). Coupled with the irreparability of many damaging 
events, this results in sustained DNA damage response activation (Fumagalli et al., 2012). 
Thus, telomeres increased propensity for, and inability to repair DNA damage allows for 
an innate-like immunity that triggers crucial response pathways (Hewitt et al., 2012). 
Similarly, the end-replication problem and telomere shortening are theorized to serve as 
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another impediment towards accumulating deleterious mutations, especially ones 
necessary for carcinogenesis.  
Finally, somatic cells have limited replicative capacity, also known as the 
Hayflick limit, due to replication-mediated terminal DNA shortening (Hayflick, 1965). 
During DNA replication the leading strand is synthesized uninterruptedly from 5’ to 3’ 
toward the unwinding replication fork; ending in a 3’ G-rich telomeric overhang. In 
contrast, the lagging strand is synthesized away from the replication fork in small 5’ to 3’ 
Okazaki fragments to satisfy the unidirectional functionality of DNA polymerases 
(Okazaki et al., 1968). As a result, about 50-100 nucleotides are progressively lost from 
the 5’ end of the lagging daughter strand (Harley et al., 1990). Thus, telomeric DNA acts 
as a buffer to alleviate loss of integral DNA sequences. As most cells continue to divide 
their telomeres become irreversibly shorter, unless otherwise re-lengthened. 
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Figure 1. Telomere structure and function. a) Once the telomeric region at the terminal 
ends of chromosomes become compromised, they no longer mitigate DNA repair 
mechanisms that may mistakenly recognize them as double stranded breaks (DSB). 
Ensuing non-homologous end-joining (NHEJ) repair results in chromosomal fusions which 
subsequently break during cellular division. This cycle of DSB fusion via NHEJ and 
breakage with continued replication results in genomic instability and consequently 
increased tumorigenic potential. b) Telomere capping is assisted by the sheltrin complex 
which is made of six proteins. TRF1, TRF2 and POT1 facilitate telomere binding 
specificity, while RAP1, TPP1 and TIN2 support localization, stability and 
interconnectivity between single and double stranded telomeric regions. Adapted from 
Doksani, 2019. c) Telomere shortening occurs as a result of the semi-conservative nature 
of DNA replication during cellular replication. The leading strand is synthesized towards 
the replication fork in the 5’ to 3’ direction. Due to the unidirectional function of DNA 
polymerase, the lagging strand is synthesized in 5’ to 3’ fragments away from the 
replication fork. Each fragment requires an RNA primer for DNA polymerase function. 
However, once the terminal primer is removed that region cannot be replicated, resulting 
in incomplete 5’ ends on daughter lagging strands. Continued replication continues to erode 
chromosomal ends. TRF1 = telomere repeat binding factor 1; TRF2 = telomere repeat 
binding factor 2; POT1 = protection of telomeres 1; RAP1 = repressor/activator protein 1; 
TPP! = tripeptidyl peptidase 1; TIN2 = TRF1/TRF2 interacting nuclear protein 2. 
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1.3. Telomere shortening and dysfunction in carcinogenesis  
Telomere shortening is hypothesized to result in uncapping of shelterin proteins 
and permissive DNA damage response (DDR) pathways. The sheltrin protein TRF2 binds 
double-stranded TTAGGG repeats and is essential for inhibiting recognition of DSBs by 
ataxia-telangiectasia-mutated (ATM) (Arnoult & Karlseder, 2015). Similarly, POT1 binds 
the single-stranded overhang and is essential for inhibiting recognition by ataxia 
telangiectasia and Rad3-related (ATR) (Denchi & de Lange, 2007). Both ATM and ATR-
mediated DDR results in activation of downstream p53-p21 and/or p16-Retinoblastoma 
cell-cycle regulating pathways (Jacobs & de Lange, 2004). Cells subsequently undergo 
apoptosis (programmed cell death) or enter senescence (non-replicative state), otherwise 
known as mortality stage 1 (M1) (Wright et al., 1989). Thus, the Hayflick limit is likely 
an intrinsic protective mechanism against cytopathology that limits the accumulation of 
mutations. If cell checkpoint regulators are dysfunctional, replication persists, and cells 
enter crisis (Shay et al., 1991) (mortality stage 2 – M2) (Wright et al., 1989). Further cell 
division is accompanied by chromosomal breakage-fusion-bridge cycles. Apoptosis is 
inevitable with continued genomic degradation unless the already shortened telomeres 
can be rescued. This selective pressure only permits the survival of cells that have 
managed to acquire the ability to re-lengthen and/or recap their telomeres and ultimately 
achieve immortalization; occurring in 1 out of 106 – 108 cells (Castro-Vega et al., 2015) 
(Figure 2). The only methods of acquiring telomere maintenance are through 
reactivation/upregulation of telomerase or via alternative lengthening of telomeres (ALT), 
a mechanism utilizing homologous recombination (Dunham et al., 2000).   
 6 
 
 
Figure 2. Telomere shortening is a selective pressure for immortalization. Every cell 
division is accompanied by telomere shortening, more so in somatic cells that lack telomere 
re-lengthening mechanisms. Eventually, short telomeres in somatic cells are recognized as 
DNA damage and senescence is triggered (M1 stage). However, premalignant cells 
harbouring mutations impacting cell-cycle/checkpoint mechanisms can bypass M1 and 
continue to divide. Continued division results in critically short telomeres and 
compounding negative effects on genomic integrity. Typically, cells will undergo apoptosis 
in this stage of crisis (M2 stage), unless they have acquired a mechanism to re-
lengthen/maintain their telomeres. Taken with permission from Shay, 2016 (Appendix G.1).  
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1.4. Telomerase component structures and enzymatic procedure  
Telomerase is a ribonucleoprotein complex that is responsible for the de novo 
synthesis of telomeric sequences (Greider & Blackburn, 1985).  This unique reverse 
transcriptase is a dimeric structure (Sauerwald et al., 2013) where each side is made of 
two core subunits: telomerase reverse transcriptase (TERT, also known as hTERT in 
humans) and telomerase RNA component (TERC) (Greider, 1990; Blackburn, 1991). 
Both TERT and TERC are sufficient and necessary for activity in vitro (Weinrich et al., 
1997). In addition, accessory proteins such as the H/ACA protein complex (NHP2, 
NOP10, GAR1 and dyskerin) are associated with telomerase activity and are required for 
various regulatory processes in vivo (Mitchell et al., 1999; Pogacić et al., 2000; Cohen et 
al., 2007) (Figure 3).  
The TERC subunit serves as a complementary internal template (3’-
CAAUCCAAUC-5’) to telomere hexameric repeats. An RNA/DNA hybrid is formed by 
binding with the 3’ G-rich overhang of the leading strand and towards the 5’ region of 
TERC. From here TERT transcribes six nucleotides (5’-GGTTAG-3’), extending the 3’ 
leading strand. Through cycles of separation, template translocation, RNA/DNA hybrid 
reformation, and TERT-mediated synthesis, the telomere 3’ overhang is repeatedly 
elongated during the synthetic phase of the cell cycle (Wu et al., 2017). The 5’ C-rich 
lagging strand end is then theorized to be filled in later by DNA polymerase alpha-
primase during the S/G2 phase of the cell cycle – though this mechanism is still under 
debate (Zhao et al., 2011).   
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Figure 3. Telomerase enzymatic component (TERT), RNA template component 
(TERC) and associated proteins. The primary components of telomerase are the RNA 
template TERC which binds to telomeric repeats using a complementary RNA sequence, 
and the enzymatic component TERT which facilitates the de novo addition of telomeric 
repeats. In addition, accessory proteins such as the H/ACA complex regulate telomerase 
activity in vivo. Taken with permission from Shay & Wright, 2019 (Appendix G.2). 
 
1.5. Telomerase activity and telomere length  
Telomerase activity (TA) and telomere length (TL) are both negatively correlated 
with developmental status. Long-term self-renewing embryonic stem cells and germ cells 
have longer telomeres and high TA (Wright et al., 1996). Interestingly, telomerase 
activity is only initiated at the blastocyst stage (Liu et al., 2007). Therefore, cleavage 
stage blastomeres which lengthen their telomeres must do so through ALT methods (Liu 
et al., 2007). Terminally differentiated somatic cells have shorter telomeres and seldom 
have telomerase activity. Some highly mitotic somatic cell types have appreciable levels 
of TA. For example, keratinocytes from the basal epidermal layer (Härle-Bachor & 
Boukamp, 1996), epithelial cells of the endometrium particularly in the late proliferative 
menstrual stage (Kyo et al., 1997; Tanaka et al., 1998) , and leukocytes (Counter et al., 
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1995). In contrast to the dogma that increased replicative capacity is a consequence of 
increased TL and TA, the majority (85-90%) of cancer cells have reactivated telomerase 
(Kim et al., 1994; Shay & Bacchetti, 1997) yet shorter telomeres than matched normal 
tissues (Barthel et al., 2017). The remaining 10-15% of cancer cells maintain telomeres 
through ALT (Heaphy et al., 2011a) and are typically of mesenchymal or neuroepithelial 
origin (Henson & Reddel, 2010; Reddel, 2014; Pickett & Reddel, 2015). The advantage 
that short telomeres confer in a carcinogenic setting has yet to be elucidated; however, 
changes in TL can certainly promote cancer cell differentiation (Hirashima et al., 2013). 
While telomerase activity is evident in most cancer cells, the enzyme levels and telomere 
length are both variable between different tumour types and individual cells within a 
single tumour (Ludlow et al., 2014; Frink et al., 2016). Although the nuances of 
telomerase reactivation in cancer are unknown, reactivation via TERT upregulation is 
well-documented (Akincilar et al., 2016).  
 
1.6. TERT structure  
The human TERT gene is located on chromosome 5, spanning about 42 kilobases. 
Once transcribed, FL-TERT spans around 4kb consisting of 16 exons and 15 introns, and 
once translated is a 127 kilodalton protein composed of 1139 amino acids (Cong et al., 
1999; Wick et al., 1999). This functional protein has four key domains: telomerase 
essential N-terminal domain (TEN) domain, telomerase RNA binding domain (TRBD), 
C-terminal extension domain (CT) and central catalytic reverse transcriptase domain (RT) 
(Autexier & Lue, 2006) (Figure 6). The TEN domain binds single stranded telomeric 
DNA, the TRBD domain is a key binding agent for TERC and contains a conserved 
telomerase-specific domain, and CT domain which is less conserved shows species-
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specific functions and in humans is essential for telomerase activity. The highly 
characterized RT domain contains seven conserved RT motifs spanning exons 4 to 11 and 
is vital for catalytic activity (Wyatt et al., 2010).  
 
1.7. Critical method of telomerase reactivation – TERT 
Both full-length (FL) TERT and TERC are considered limiting factors for 
telomerase activity (Cohen et al., 2007; Xi & Cech, 2014). Quantification studies have 
shown more ubiquitous TERC expression (5000-10,000 molecules per cell), in 
comparison to scarce TERT expression levels (1-40 molecules per cell) (Yi et al., 2001; 
Withers et al., 2012). The half-life of TERT in cancer cells is also estimated at hours 
versus weeks for TERC (Xu et al., 1999; Yi et al., 1999), and ectopic expression of 
TERT is sufficient for immortalization in-vitro (Bodnar et al., 1998). Therefore, TERT-
mediated telomerase reactivation has become a primary field of cancer research. The 
regulatory mechanisms potentially altering TERT expression during malignant 
transformation are complex and diverse: transcriptional regulators, promoter mutations, 
epigenetic changes, alternative splicing, micro-RNA (miRNA), long non-coding RNA 
(lncRNA) and post-translational modification (Jie et al., 2019).  
Transcriptionally, TERT can be regulated through transcription factor (TF) 
binding to the core or proximal promoter. Changes in TF protein expression of positive 
(e.g. cMYC, NF-kB, STAT3) or negative regulators (e.g. E2F1, MAD1) may increase or 
decrease TERT expression (Ramlee et al., 2016). Adding to the complexity are alterations 
in upstream regulators of these TFs. For example, p300 (Faiola et al., 2005) and Aurora-
A (Yang et al., 2004) help stabilize and increase the expression of c-MYC, which in-turn 
promotes TERT expression. Some TFs such as SP1 (specificity protein 1) have dual roles, 
 11 
stimulating expression in telomerase-positive cells (Kyo et al., 2000) while recruiting 
epigenetic silencers in telomerase-negative cells (Won et al., 2002). Consolidating an 
exhaustive list of TF regulators with their weighted effects on TERT expression is highly 
improbable, and while more prominent canonical regulators exist, their pleiotropic effects 
on gene expression introduce difficulty in drawing conclusions solely between TERT 
regulation and phenotypic outcomes.  
In contrast, TERT promoter mutations impose a direct effect. Originally 
discovered in melanoma, -124 (C > T) and -146 (C > T) also called C288T and C250T 
respectively, are two hotspot mutations (Horn et al., 2013; Huang et al., 2013), 
accounting for 85% of somatic promoter mutations (Bell et al., 2016; Gaspar et al., 
2018). The single nucleotide change presents a novel consensus binding motif for E-
twenty-six TFs that cooperate with mutated TERT promoters to enhance transcription up 
to 2-fold (Horn et al., 2013; Huang et al., 2013). These promoter mutations have been 
commonly found (≥ 15%) but not exclusively in cancers with low self-renewal rates 
(Heidenreich & Kumar, 2017). It is theorized that tissues with appreciable TERT 
expression would have neutral non-selective effects from promoter mutations in early 
stages of transformation, whereas low self-renewing tissues would immediately confer a 
proliferative advantage (Chiba et al., 2015). Within prevalent TERT promoter-mutated 
cancer types, mutations are associated with poor clinical survivability and increased 
tumour aggression (Ramlee et al., 2016). Moreover, cancer cell lines with heterozygous 
promoters display contrasting epigenetic markers between WT and mutant promoters. 
Active chromatin markers (H3K4me2/3) are present on mutant TERT promoters, whereas 
suppressive chromatin markers (H3K27me3) are present on WT TERT promoters (Stern 
et al., 2015). Epigenetic changes have profound effects on gene expression and evidence 
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suggests the TERT gene in somatic cells is embedded in a condensed chromatin 
environment (Wang & Zhu, 2004).  
Cancer types that do not harbour frequent TERT promoter mutations may change 
methylation patterns to upregulate TERT expression (Lee et al., 2019). Traditionally 
promoter methylation is associated with gene silencing and total methylation of the TERT 
promoter leads to complete transcriptional inhibition (Renaud et al., 2007). Although, 
some studies have observed the opposite effect from promoter methylation status on 
expression. For example, the transcriptional repressor CTCF binds the first exon of TERT 
when unmethylated (Renaud et al., 2007). Equally, histone acetylation impacts gene 
accessibility by changing the chromatin environment. Hyperacetylation of histones H3 
and H4 is associated with high TERT expression in telomerase-positive cancer cells, 
while hypomethylation is associated with low TERT expression in ALT cells (Atkinson et 
al., 2005). These epigenetic changes likely work in concert and investigating pre- and 
post-differentiation in human teratocarcinoma cells has suggested that histone 
deacetylation initiates early TERT inhibition, while promoter methylation maintains this 
inhibitory state (Lopatina et al., 2003).  
Supplementing the pre-transcriptional level of regulation are post-transcriptional 
and post-translational methods. Briefly, post-translationally TERT can be phosphorylated 
or ubiquitinated. The effects of phosphorylation status are variable depending on amino 
acid residue, cell type and sub-cellular localization of TERT. Ubiquitination typically 
leads to increased TERT degradation (Jie et al., 2019). Post-transcriptionally, mRNAs are 
affected by miRNA and alternative splicing; the former bind to 3’-UTR (untranslated 
region) to hinder translation while the latter results in creating a diversity of gene variants 
or isoforms (Jie et al., 2019). However, since TERT is minimally expressed compared to 
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other genes and only full-length TERT has canonical function, alternative splicing is 
proposed as a regulatory method for telomerase activity, which if hijacked could 
encourage carcinogenesis.  
 
1.8. TERT alternative splice variants  
Eukaryotic splicing conventionally involves the end-to-end joining of exons 
through the removal of intronic sequences in precursor mRNA to generate mature 
mRNA. However, exonic regions may be constitutive or alternative, the latter giving rise 
to ASVs. This process is performed by the spliceosome, a ribonucleoprotein made of five 
core components (U1, U2, U4, U5 and U6) and hundreds of accessory proteins (Jurica & 
Moore, 2003). Splicing site usage is regulated by cis-regulatory sequences that are bound 
by trans-acting factors to either enhance or inhibit the removal of intronic or exonic 
regions (Roca et al., 2013). Changes in trans-factor expression and/or somatic mutations 
that abolish or create novel splice sites can significantly alter a gene’s functional 
penetrance, especially for low-abundance genes such as TERT.  
Currently, 22 human TERT ASVs have been identified in-vitro, which are 
comprised of various combinations of independent splicing events (Hrdlicková et al., 
2012). Most of these events involve the removal of or addition into the RT domain, 
resulting in catalytically inactive proteins if translated (Liu et al., 2017b). The most 
characterized splice events occur within the RT domain and include the alpha deletion, 
beta deletion and gamma deletion. The alpha deletion occurs from a splice site within 
exon 6, resulting in the removal of 36 nucleotides whilst maintaining the canonical open 
reading frame (ORF) (Yi et al., 2000). The alpha TERT variant (α-TERT) is expressed 
weakly and quantified at 5% of total TERT transcripts in immortal human cells (Yi et al., 
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2001). The beta deletion results in the skipping of exons 7 and 8 and creates a premature 
stop codon in exon 10 (Yi et al., 2000). The beta TERT variant (ß-TERT) is likely the 
most abundant variant in stem and cancer cells (Listerman et al., 2013; Bollmann, 2013) 
but largely undergoes nonsense-mediated decay (NMD) (Nicholson et al., 2010). 
However, some evidence suggests some ß-TERT is translated into a truncated protein 
(Listerman et al., 2013). Regulation of the ß-deletion splicing event has been more 
thoroughly investigated than other splice events and two factors, NOVA1 and PTBP1, 
have been shown to directly bind TERT pre-mRNA in lung cancer cells to hinder ß-
deletion splicing and promote FL-TERT (Ludlow et al., 2018; Sayed et al., 2019). The 
gamma deletion results in the skipping of exon 11 but maintains the canonical ORF 
(Hisatomi et al., 2003). Gamma TERT (γ-TERT) has displayed cell/tissue-specific 
expression; while present in gastric and hepatocellular carcinoma is not in colorectal cell 
lines (Nagao et al., 2004). The combination of these splice events to create αß, αγ, ßγ and 
αßγ-TERT can appear in some cell-types and is comparatively lowly expressed (Liu et 
al., 2017b). In addition to these highly defined TERT ASVs also exists delta 4-13 (∆4-13 
TERT), deletion of exon 2, (∆2 TERT) and insertion ASVs (INS1 to -4) (Ludlow et al., 
2019). (Figure 4). 
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Figure 4. mRNA structure of commonly investigated TERT isoforms and those 
annotated in Ensembl Build 93. FL-TERT consists of 16 exons that make up four 
domains: TEN, TRBD, RT and CT. Splicing can involve deletions which are marked with 
downward diagonal stripes, or insertions which are marked with smaller boxes and an 
arrowhead marking the insertional point. ORFs are shown with a light red shade layered 
over the mRNA structure. Yellow star indicates transcripts that are annotated in Ensembl 
Build 93. Information about splicing events are detailed on the right for each transcript. 
based on Ensembl transcript nomenclature FL-TERT is also referred to as TERT_581.9, ß-
TERT as TERT_104.2, γ-TERT as  TERT_602.10 and αßγ-TERT as TERT_137.6. All 
Ensembl transcripts are either automatically generated from the Ensembl genebuild 
pipeline or manually annotated by the human and vertebrate analysis and annotation 
(HAVANA); supported by transcriptional evidence either from complementary DNA, 
expressed sequence tags, or protein sequences. TERT_238.6, TERT_656.1 and 
TERT_877.1 transcripts have not been experimentally confirmed so are labeled as “novel 
transcripts”. Telomerase essential N-terminal domain (TEN); Telomerase RNA binding 
domain (TRBD); C-terminal extension domain (CT); Central catalytic reverse transcriptase 
domain (RT); Open-reading frame (ORF).  
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1.9. Canonical functions of TERT ASVs  
Only FL-TERT retains canonical enzymatic RT functionality, while TERT ASVs’ 
function may simply be their lack of RT activity. In other words, alternative splicing may 
regulate telomerase activity pre-translationally by limiting levels of FL-TERT mRNA or 
post-translationally by binding to and sequestering necessary components for telomerase 
activity (Liu et al., 2017b). Notably, telomerase functions in a dimeric structure, and 
while TERC’s abundance may be minimally affected by TERT ASV sequestration, FL-
TERT’s minimal expression imposes an increased susceptibility to possible sequestration 
effects. Studies support the existence of this mechanism during early development. Fetal 
kidney tissue displays telomerase activity which becomes suppressed after the 15th 
gestational week. Simultaneously, TERT ASVs (mostly ß-TERT) begin expression and 
are maintained until the 21st gestational week (Ulaner et al., 1998). Similarly, during fetal 
brain development telomerase activity declined between weeks 6 to 17 post-conception 
with a concomitant decrease in TERC, increase in α-TERT and no change in FL-TERT 
expression (Ishaq et al., 2016). This indicates a possible splicing-mediated inhibition of 
telomerase activity before more permanent mechanisms can occur, such as epigenetic 
silencing. Historically, somatic cells were presumed to have zero TERT expression as a 
result of poor primer orientation within spliced regions for PCR experiments (Hrdlicková 
et al., 2012). Now it is clear somatic cells do express TERT, but they are predominantly 
ASVs (Hrdlicková et al., 2012).  
The α-TERT variant translates into a dominant-negative protein that results in 
telomere shortening and apoptosis when overexpressed in some telomerase-positive cells 
(Colgin et al., 2000; Yi et al., 2000). Likewise, the γ-TERT variant maintains the 
canonical ORF (Figure 6) and if expressed abundantly in specific tissue types may also 
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function as a dominant-negative protein (Liu et al., 2017b). The ß-TERT variant is 
proposed to function similarly if translated into a truncated protein because it also retains 
the TEN and TRBD domains (Akincilar et al., 2015) (Figure 6). The major caveat in 
TERT ASV functional research has been the lack of isoform specific antibodies for 
endogenous protein quantification/localization. Other TERT ASVs telomerase-related 
consequences are largely unknown but can be inferred to have a parallel function to the 
aforementioned ASVs, if the ORF is maintained with vital domains intact and transcripts 
are successfully translated.  
 
1.10. Non-canonical functions of FL-TERT and TERT ASVs  
In addition to combatting telomere attrition, TERT has defined non-canonical 
extra-telomeric roles. Primarily by regulating gene expression as a transcriptional 
(co)factor, TERT is involved in Wnt/ß-catenin (Choi et al., 2008; Zhang et al., 2012) and 
Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling (Ghosh 
et al., 2012). These pathways control phenotypes exacerbated in cancer, namely cell 
survival, proliferation and migration. Recent evidence has shown that ALT tumours may 
have decreased metastatic potential due to the lack of non-canonical functions (Romaniuk 
et al., 2019). This notion is reinforced by studies demonstrating TERT’s positive relation 
to vascular endothelial growth factor (VEGF) (Liu et al., 2016), up-regulation of growth-
promoting genes and down-regulation of pro-apoptotic genes (Smith et al., 2003) and 
mitochondrial resistance to stress (Haendeler et al., 2009; Gordon & Santos, 2010). While 
the nuances of these pathways have yet to be teased out, it is clear TERT promotes a pro-
proliferative/survival state which complements the immortal phenotype it also confers, 
providing an advantage for cancer cells to flourish.  
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With respect to TERT ASVs, despite the lack of substantiating evidence there are 
some cases of non-canonical functions. The ß-TERT variant when overexpressed in 
breast cancer cells results in reduced telomerase activity but also protects cells from 
apoptosis when exposed to chemotherapy (Listerman et al., 2013). Despite the lack of 
telomerase activity, ALT sarcoma cell lines expressed the ∆4-13 TERT variant and 
induced proliferation with stimulation of Wnt-signaling when overexpressed (Hrdlicková 
et al., 2012). Finally, sterically hindering alpha or beta splice sites in order to shift 
splicing patterns results in biased spontaneous differentiation of human embryonic stem 
cells towards endomesodermal and neuroectodermal lineages (Radan et al., 2014). While 
TERT ASVs downregulate telomerase activity during fetal development, changes in ASV 
ratios may also result in or be a consequence of fate determination. An evaluation of 
global transcriptomic changes, through techniques such as RNA sequencing rather than 
measuring a set of lineage markers, would elucidate developmental consequences 
resulting from altered TERT splicing patterns. 
 
1.11. RNA sequencing overview  
 Sequencing has become a mainstay experimental assay in the “omics” field as the 
costs have dropped almost 100-fold over the last decade (Wetterstrand KA, 2019).  
During this period, RNA sequencing (RNA-seq) techniques have correspondingly 
improved, steadily overtaking quantitative polymerase chain reaction (PCR) and 
microarrays for investigating differential gene expression. The general RNA-seq steps 
have remained unchanged: library preparation, sequencing and data analysis (Figure 5). 
Various platforms will require different techniques for library construction. Standard 
workflow entails a wet-lab preparatory stage involving RNA extraction, mRNA 
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enrichment (typically via poly-A selection or rRNA depletion) and adaptor-ligated 
sequencing (Griffith et al., 2015), following which, a dry-lab (computational) stage 
includes initial processing for quality control, alignment/assembly of reads to reference 
genome, quantification, normalization and downstream analyses (Stark et al., 2019). 
Taken together, this computational phase is known as a “pipeline.” The latter steps of the 
computational phase attempts to count the number of reads that align to a given 
gene/transcript, while accounting for the total number of reads and the gene/transcript 
length. However, some reads (called multireads) will align to many transcripts. RNA-seq 
by Expectation-Maximization (RSEM) has been a mainstay tool for the past decade to 
circumvent the ambiguity of multireads (Li & Dewey, 2011). Simply put, RSEM assumes 
each read can only map to one transcript and uses an iterative probabilistic algorithm to 
determine which alignment has the maximum likelihood. Researchers have numerous 
tools at their disposal for the entrenched pipeline steps, as well as, novel tools such as 
alignment-free integrated assembly and quantification (Bray et al., 2016; Patro et al., 
2017). These tools are becoming more popular because of their increased speed by 
avoiding mapping each read to the reference genome, but instead using pseudoalignment 
to transcript sequences helps determines the potential transcript of origin. While some 
biases can be mitigated through interventions such as batch-correction (Goh et al., 2017), 
with over 100 unique RNA-seq protocols (Stark et al., 2019), inter-experimental 
comparisons can easily become complicated.   
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Figure 5. Typical RNA-sequencing workflow involves wet-lab library preparation 
followed by computational data management. Once the samples of interest are collected, 
depending on the experimental goal, RNA much be isolated. In the case of mRNA, poly-
A-selection would select for only mature mRNA. To increase the stability, a 
complementary DNA library is generated with functional requirements for sequencing such 
as adaptors/linkers. Post-sequencing reads are aligned to a reference genome/transcriptome 
and further downstream analyses are conducted for quantification. An adapted version from 
Griffith et al., 2019, taken from Technology Networks.   
 
 
1.12. Rationale for Pan-Cancer bioinformatic analysis of TERT ASVs  
 To date, TERT has been experimentally investigated independently in numerous 
human cancer types and cell lines. Despite the commonality of predominant FL-TERT 
expression and the prevalence of the ß-TERT variant, with respect to transcript quantities 
and variant ratios, the expression of TERT ASVs appears to be tumour and cell-type 
specific (Ludlow et al., 2014; Khosravi-Maharlooei et al., 2015; Liu et al., 2017b; 
Rowland et al., 2019). The canonical inhibitory function of major TERT splice variants 
are based on structural analyses and a handful of overexpression studies. However, the 
canonical functions of less prevalent TERT ASVs and non-canonical functions of TERT 
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ASVs remain largely elusive. While the negative effect of TERT promoter mutations on 
prognosis is clear for cancer types where these mutations are frequently observed, the 
prognostic and or diagnostic effect of TERT ASV expression patterns remains 
uninvestigated. Much of what is known about TERT structure and function has been 
extrapolated from studies in other species due to high structural conservation. 
Unfortunately, TERT alternative splicing in humans is distinct from other common 
laboratory species, including murine TERT (Sayed et al., 2019).  
Traditionally, investigations into TERT ASVs have been performed using the in-
vitro PCR assay. One major shortcoming has been the inability to assess multiple splice 
events as each primer/probe can only target a single splice event. Furthermore, the 
protocol variation across studies minimizes any relationships that can be drawn from 
TERT ASVs. Recently, studies have been utilizing a Pan-Cancer bioinformatic 
perspective towards telomere research (Barthel et al., 2017; Luo et al., 2019; Slusher et 
al., 2020). Of note, Barthel et al. investigated telomere length and TERT somatic 
alterations across 31 cancer types and Luo et al. assessed the telomerase-associated gene 
signature differences between TERT-high and TERT-low expression tumours. Most 
recently, Slusher et al. reviewed TERT alternative splicing and briefly described TERT 
isoform prevalence across 31 cancer types. However, there has yet to be a Pan-Cancer 
characterization of TERT isoform expression patterns between matched tumour and 
normal tissues and between cancer-specific subtypes. By expanding the breadth and depth 
of inquisition, we may uncover both novel conserved and specialized expression patterns, 
functions and clinical utility.  
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1.13. Cancer cell line TERT expression heterogeneity  
In addition to diversity in TERT expression across tumour and cell types, there is 
paralleled heterogeneity across cancer cell lines. A Pan-Cancer cell line investigation on 
TERT isoform expression found no association with origin tumour type, indicating highly 
variable expression patterns (Khosravi-Maharlooei et al., 2015). In another study, 
Rowland et al. used single-molecule RNA fluorescent in situ hybridization (FISH) (Raj et 
al., 2008) targeting TERT exonic and intronic sequences to determine the number of 
RNA transcripts and active transcription sites (Rowland et al., 2019). They found 
substantial heterogeneity in the number of active transcription sites both between 
different cell lines and between different cells within the same cell lines. The number of 
active transcription sites did not reflect the allelic classification determined using DNA 
FISH (Huang et al., 2015), expected but not observed to be 2:1 for monoallelic and 2:2 
for biallelic. While investigations into mechanisms of TERT re-activation, expression 
attenuation, splicing shifts and their consequential phenotypic outcomes have been and 
continue to be conducted in various cancer types via cell line models, these results 
illuminate the necessity of suitable cancer cell line selection during experimental design. 
Cell lines that accurately reflect TERT isoform expression observed in primary tumours 
will provide more translatable functional inferences.  
 
1.14. Research Objectives  
 The TERT ASV expression profile is heterogenous and has been characterized 
using a myriad of in-vitro protocols. Moreover, the lack of ASV-specific antibodies limits 
exploration into the proteomic expression and functions of TERT-ASVs. Therefore, the 
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primary objective of this thesis was to characterize the expression of TERT across tissue 
types utilizing a uniform methodology and infer telomeric cellular functions.  
Telomere maintenance in necessary for neoplastic transformation. Thus, the 
prospect of telomere maintenance targeted therapies continues to appeal to researchers. 
Interestingly, TERT ASVs confer proliferative, anti-apoptotic and cell fate determinative 
phenotypes through non-canonical pathways. Thus, the secondary objective was to 
determine the prognostic impact of TERT ASV expression on cancer.  
Unfortunately, TERT splicing remains both unique in humans and displays 
massive heterogeneity, so model systems must be developed to study their effects in a 
reproducible manner. Cost-effectiveness and high-throughput capacity make cancer cell 
lines ideal experimental models. Accordingly, the third objective was to identify suitable 
cancer cell lines for primary tumours based on TERT ASV expression patterns.  
 
1.15. Governing Hypothesis  
 I hypothesized that tumours will have unique TERT ASV expression patterns 
from matched normal tissue and amongst other cancer types and these distinct expression 
patterns will infer different functional consequences.  
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Chapter 2 – Methods 
 
2.1. RNA sequencing data 
2.1.1. Toil recomputed (TCGA & GTEx) dataset 
 Sample phenotypic characteristics and gene/transcript-level expression data for 
the TCGA and GTEx projects were downloaded from the UCSC Xena server from the 
UCSC Toil RNA-seq Recompute data hub (https://toil.xenahubs.net). Expressions data 
were presented in normalized format of transcripts per million (TPM) values. This is done 
by dividing the length-normalized transcript of interest by the sum of all length-
normalized transcripts, then multiplying by 106 (1 million). TPM values represent a 
relative abundance, as the sum of all TPM values in a sample will equal one million.   
 
For example, a gene’s TPM value of “2” would indicate that if one million total 
transcripts were sequenced from a sample, then two transcripts would be from the gene of 
interest. The average TPM is equal to one million divided by the number of annotated 
transcripts. The total number of annotated transcripts for the Toil Recomputed dataset 
was 198,620, resulting in an average of ~5 TPM.   
 
2.1.2. RNA sequencing data management and filtering  
 The Toil Recompute dataset was first filtered by project for TCGA and GTEx 
samples only. The paediatric cancer project “TARGET” was removed to focus on adult 
cancers because the average age of GTEx sample donors was 53.4 (21 – 70 years old). 
After which, TCGA samples were filtered for only primary solid tumours and primary 
blood derived tumours. The filtered TCGA dataset consisted of 10,535 samples, of which 
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9,358 samples were primary solid or blood-derived tumours with RNA-sequencing data 
(Figure 6). These samples originated from 33 different cancer types. The GTEx dataset 
consisted of 7,862 samples from 30 tissue types, of which 19 tissue types (n = 3482) 
corresponded with TCGA tumour tissue types (Figure 6). Specifically, for GTEx samples; 
brain cortex and brain frontal cortex were chosen from normal brain GTEx subtypes, and 
esophagus mucosa was chosen from normal esophagus GTEx subtypes. Some GTEx 
tissue types were compared to multiple TCGA tumour types. Normal GTEx blood 
samples were compared to both Acute Myeloid Leukemia (LAML) and Lymphoid 
Neoplasm Diffuse Large B-cell Lymphoma (DLBC). Normal GTEx brain cortex samples 
were compared to both Brain Lower Grade Glioma (LGG) and Glioblastoma multiforme 
(GBM). Finally, normal GTEx lung samples were compared to both Lung 
adenocarcinoma (LUAD) and Lung squamous cell carcinoma (LUSC). After removing 
samples not expressing TERT (zero TPM) the TCGA dataset was made of 7887 samples 
and the GTEx dataset was made of 2099 samples (Figure 6). These samples were 
removed because the focus was on telomerase-based telomere re-lengthening and samples 
not expressing TERT are thought to utilize ALT. However, after this removal the normal 
bladder, cervical and kidney tissues had small sample sizes (~1%) in comparison to the 
sum of matched tumour type samples and were consequently removed. In total there were 
19 matched normal-tumour comparisons (Table 1).  
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Figure 6. Data filtering workflow from the total TOIL recomputed dataset to only 
TERT-positive TCGA and matched GTEx samples. The total TOIL dataset has 19,131 
samples. From here, TARGET (paediatric cancers), normal tissue types without matched 
tumour tissue types, and TERT-negative samples were removed. In total, there were 
2,099 normal (GTEx) samples and 7,887 tumour (TCGA) samples used.  
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Table 1. Tumour (TCGA) and normal (GTEx) comparison pairs 
 
 
2.2. Clinical data  
2.2.1. Clinical data acquisition 
Clinical information (tumour stage, tumour grade, patient gender and patient age 
at diagnosis), survival and progression data related to TCGA tumour samples were taken 
from Liu et al., 2018a.  
 
2.2.2. Clinical data management and filtering  
Clinical variables were matched with Toil recomputed TCGA RNA-seq 
expression data for each sample. Overall survival (OS) was used for all cancers except 
TCGA Study Abbreviation Cancer Type Matched GTEx Normal Tissue
ACC (n= 53) Adrenocortical carcinoma Adrenal (n= 11)
BRCA (n= 1032) Breast invasive carcinoma Breast (n= 79)
COAD (n= 288) Colon adenocarcinoma Colon (n= 183)
DLBC  (n= 47) Lymphoid Neoplasm Diffuse Large B-cell Lymphoma Blood (Whole) (n =259)
ESCA (n= 176) Esophageal carcinoma Esophagus (n= 253)
GBM (n= 143) Glioblastoma multiforme Brain (Cortex) (n= 189)
LAML (n= 171) Acute Myeloid Leukemia Blood (Whole) (n =259)
LGG (n= 317) Brain Lower Grade Glioma Brain (Cortex) (n= 189)
LIHC (n=350) Liver hepatocellular carcinoma Liver (n= 18)
LUAD (n= 499) Lung adenocarcinoma Lung (n= 142)
LUSC (n= 490) Lung squamous cell carcinoma Lung (n= 142)
OV (n= 412) Ovarian serous cystadenocarcinoma Ovary (n= 15)
PAAD (n= 154) Pancreatic adenocarcinoma Pancreas (n= 23)
PRAD (n= 461) Prostate adenocarcinoma Prostate (n= 49)
SKCM (n= 97) Skin Cutaneous Melanoma Skin (n= 490)
STAD (n= 408) Stomach adenocarcinoma Stomach (n= 134)
TGCT (n= 146) Testicular Germ Cell Tumors Testes (n= 164)
THCA (n= 161) Thyroid carcinoma Thyroid (n= 60)
UCEC (n= 178) Uterine Corpus Endometrial Carcinoma Uterus (n= 14)
BLCA (n= 399) Bladder Urothelial Carcinoma Bladder (n= 2)
CESC (n= 301) Cervical squamous cell carcinoma and endocervical adenocarcinoma Cervix (n= 5)
KICH (n= 18) Kidney Chromophobe Kidney (n= 9)
KIRC (n= 368) Kidney renal clear cell carcinoma Kidney (n= 9)
KIRP (n= 119) Kidney renal papillary cell carcinoma Kidney (n= 9)
CHOL (n= 32) Cholangiocarcinoma N/A
HNSC (n= 506) Head and Neck squamous cell carcinoma N/A
MESO (n= 83) Mesothelioma N/A
PCPG (n= 39) Pheochromocytoma and Paraganglioma N/A
READ (n= 92) Rectum adenocarcinoma N/A
SARC (n= 111) Sarcoma N/A
THYM (n= 119) Thymoma N/A
UCS (n= 55) Uterine Carcinosarcoma N/A
UVM (n= 62) Uveal Melanoma N/A
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DLBC, PCPG, TGCT and THYM. Progression-free interval was used for call cancers 
except LAML and PCPG. Liu et al. described using caution in drawing results from PFI 
or OS in specific cancer types with small sample size, small number of events, or needing 
longer follow-up times. Specifically, caution was noted for PFI with DLBC and KICH, as 
well as caution for OS with BRCA, KICH, LGG, PRAD, READ, and THCA.  
There were 51 samples with missing age at diagnosis and 46 samples where 
patients were 90 years or older but were capped at 90 because of Health Insurance 
Portability and Accountability Act (HIPAA) regulations (Liu et al., 2018a). Redacted 
cases were also removed. Clinical stages were used for CESC, DLBC, OV, UCEC and 
UCS. Masaoka stage was used from THYM. All other cancer types used American Joint 
Committee on Cancer (AJCC) staging. “Low-grade” was converted to grade one and 
“high-grade” was converted to grade three; this applied to BLCA and UCEC.  
An OS event (i.e. death) was taken from a patient death of any cause. Time to an 
OS event was taken from days to death or days to last contact, whichever was larger. A 
PFI event (i.e. progression) was taken from a patient having new tumor event whether it 
was a progression of disease, local recurrence, distant metastasis, new primary tumors at 
any site, or died with the cancer without new tumor event, including cases with a new 
tumor event whose tumour type was not available. Time to a PFI event was taken 
according on which PFI event was used to determine progression for that specific patient.  
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2.3. Cancer cell line data 
2.3.1. CCLE data acquisition 
Transcript expression (CCLE_RNAseq_rsem_transcripts_tpm_20180929.txt.gz) 
and phenotypic characteristics (Cell_line_annotations_20181226.txt) were downloaded 
from the CCLE database (https://portals.broadinstitute.org/ccle/data).  
 
2.3.2. CCLE data management and filtering 
 Unlike Toil recomputed RNA-seq data using the GRCh38 reference genome, 
CCLE RNA-seq data was computed using the dated GRCh37 reference genome. 
Additionally, the CCLE recharacterization was annotated using Gencode v19 (equivalent 
to Ensembl Build 75) (Flicek et al., 2014) as opposed to Gencode v23 (equivalent to 
Ensembl Build 93) (Zerbino et al., 2018) used for Toil recomputed TCGA and GTEx 
RNA-seq data. In this dated annotation there are the seven TERT transcripts present in 
Ensembl Build 93, plus an additional TERT transcript with complete deletions of exons 7 
and 8 (i.e. ß-deletion), that we abbreviated as TERT_820.5. The ß-deletion, when 
translated results in truncated protein from a premature stop codon in exon 10. The only 
difference between the TERT_104.2 ß-TERT transcript and the additional TERT_820.5 
ß-TERT transcript was that TERT_820.5 included exons beyond the protein truncation 
point (Appendix B.2). However, this does not change the protein length which is 807 
amino acids for both transcripts. In order to compare Toil recomputed TCGA and GTEx 
RNA-seq data with CCLE RNA-seq data, TERT_820.5 expression was combined with 
TERT_104.2 in the CCLE dataset as both transcripts had the same sole ß-deletion 
splicing event. After doing so, all datasets had seven TERT transcripts and could be 
 30 
compared. There were 19 tissue types from CCLE that crossed over between 
TCGA/GTEx tissue types (Table 2).  
 
 
Table 2. Samples used for comparing CCLE, TCGA and GTEx TERT isoform 
expression patterns 
 
CCLE SAMPLES TCGA SAMPLES GTEX SAMPLES 
Biliary Tract CHOL N/A 
Haematopoietic and Lymphoid Tissue DLBC 
LAML 
Blood – Whole 
 
Autonomic Ganglia 
Central Nervous System 
GBM 
LGG 
PCPG 
Brain – Cortex 
Brain – Frontal Cortex 
 
 
 
Breast BRCA Breast 
 
Large Intestine COAD Colon 
 
Endometrium CESC 
UCEC 
UCS 
Cervix 
Uterus 
 
 
 
Esophagus ESCA Esophagus – Mucosa 
 
Kidney KIRC 
KIRP 
KICH 
Kidney - Cortex 
 
 
 
Liver LIHC Liver 
 
Lung LUAD 
LUSC 
Lung 
 
 
Ovary OV Ovary 
 
Pancreas PAAD Pancreas 
 
Prostate PRAD Prostate 
 
Pleura MESO N/A 
 
Skin SKCM Skin 
 
Soft Tissue SARC 
UCS 
N/A 
 
 
Stomach STAD Stomach 
 
Thyroid THCA Thyroid 
 
Urinary Tract BLCA Bladder 
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2.4. Telomere Length and Signature Score Data 
 Telomere length (TL) ratio values were taken from Barthel et al., with detailed 
methods found in Appendix C.1 (Barthel et al., 2017). LAML and MESO did not have 
telomere length data. Briefly, TL was quantified using TelSeq (Ding et al., 2014) for both 
TCGA tumour samples and either matched normal tissue (NT) or matched normal blood 
(NB) samples. Tumour TL was divided by matched normal TL to generate a TL ratio. 
The majority of normal samples were NB rather than NT, except for kidney samples. 
Comparing within tissues, I found NT samples had significantly longer (p < 0.05) 
telomere length estimates in bladder, liver, lung and stomach tissue than NB (Appendix 
B.3). Therefore, TL ratios calculated using NT were excluded, with the exception of 
kidney samples because of the small sample size among NB calculated TL ratios.  
 Telomerase activity-related signature scores were calculated by summing the 43 
gene TPM expression values from the Toil recomputed RNA-seq dataset. Briefly, Barthel 
et al., performed differential gene expression analysis on Gene Expression Ominibus 
microarray data from four telomerase positive and four telomerase negative de-
differentiated liposarcoma samples. This analysis resulted in 1302 genes that were 
enriched (fold-change ≥ 1.5) in telomerase positive samples. After refinement this list was 
reduced to 43 genes (Appendix C.2) and validated, but did not reach significance, in 
eleven urothelial cell carcinoma cell lines (Rho=0.58, p = 0.07). 
 
2.5. TCGA tumour subtype data acquisition 
 TCGA tumour subtype data were taken from tissue-specific landmark papers that 
investigated molecular differences within a tumour type or set of related tumour types 
(Table 3). The “selected subtype” had the most distinctive classification so it was used. 
 32 
Table 3. Selected subtypes for each TCGA cancer type identified through 
independent molecular profiling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COCA = cluster of clusters analysis 
 
2.6. Clustering-based analyses 
 Uniform Manifold Approximation and Projection (UMAP) was used for 
clustering (McInnes et al., 2018). UMAP projections require input variables that for 
number of neighbours, number of components and the distance metric. The “Manhattan” 
metric was used to compute the distances of inputted sample data. A python script 
CANCER TYPE SELECTED SAMPLE # REFERENCE PAPER 
ACC DNAmeth 50 (Zheng et al., 2016) 
BLCA mRNA 373 (Robertson et al., 2017a) 
BRCA COCA 737 (Berger et al., 2018) 
CESC COCA 94 (Berger et al., 2018) 
CHOL COCA 30 (Farshidfar et al., 2017) 
COAD  Molecular 234 (Liu et al., 2018c) 
ESCA  Molecular 34 (Liu et al., 2018c) 
GBM DNAmeth 136 (Ceccarelli et al., 2016) 
HNSC mRNA 233 (TCGA Network, 2015) 
KICH Eosinophilic 15 (Davis et al., 2014) 
KIRC mRNA 189 (TCGA Network, 2013) 
KIRP COCA 30 (Linehan et al., 2016) 
LGG DNAmeth 312 (Ceccarelli et al., 2016) 
LIHC iCluster 127 (TCGA Network, 2017a) 
LUAD iCluster 151 (TCGA Network, 2014a) 
LUSC mRNA 42 (TCGA Network, 2012) 
OV COCA 45 (Berger et al., 2018) 
PAAD Basal 115 (TCGA Network, 2017b) 
PCPG mRNA 39 (Fishbein et al., 2017) 
PRAD Mutation/Fusion 264 (TCGA Network, 2015b) 
READ  Molecular 76 (Liu et al., 2018c) 
SARC iCluster 80 (TCGA Network, 2017c) 
SKCM Mutation 51 (TCGA Network, 2015c) 
STAD  Molecular 337 (Liu et al., 2018c) 
TGCT Molecular 134 (Shen et al., 2018) 
THCA mRNA 109 (TCGA Network, 2014b) 
THYM COCA 106 (Radovich et al., 2018) 
UCEC  COCA 45 (Berger et al., 2018) 
UCS  COCA 49 (Berger et al., 2018) 
UVM mRNA 62 (Robertson et al., 2017b) 
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iterated through neighbour values of 2, 4, 8, 16, 32, 64 and 128, as well as, component 
values of 2, 3, 4, 5, and 8 for each neighbour value to generate a maximum of 35 
projections. The dimension coordinates of each sample point were extracted from a 
representative projection to perform an enrichment analysis based on the selected 
phenotypic trait used for clustering. Principal component analysis (PCA) was used for 
each cancer type and matched normal tissue to visualize the differences in isoform 
expression patterns. The variables included were the seven TERT transcripts’ expression 
values. The PCA plots were made using the first two principal components. 
 
2.7. Statistical analysis  
2.7.1. RNA sequencing data analysis 
 All data were analyzed using R Version 3.6.3 (R Core Team, 2013). A Wilcoxon 
rank sum test (also known as the Mann-Whitney U-test) was used for any two-group 
comparisons. Three groups or greater comparisons were performed using the Kruskal 
Wallis test and pairwise Mann–Whitney U-tests were performed post-hoc. TERT 
expression and isoform percentage comparisons across cancer types used a Bonferroni 
corrected p-value for the total number comparisons (significant if p < 0.05/285 or 
~0.000175). TERT isoform function correlation analysis based on signature score 
expression was computed using a Spearman’s correlation and Bonferroni corrected p-
value for total number of comparisons (significant if p < 0.05/231 or ~0.000216). TERT 
isoform function analysis based on telomere length was computed using a Spearman’s 
correlation and Bonferroni corrected p-value for total number of comparisons (significant 
if p < 0.05/465 or ~0.000108). ß-deletion splicing factor analysis across cancer types used 
a Bonferroni corrected p-value for the total number of comparisons (significant if p < 
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0.05/33 or ~0.00152). Not all samples with RNA-seq expression data had telomere length 
or subtype classification, hence these sample sizes were smaller than the analyses based 
solely on RNA-seq expression values. 
 
2.7.2. Survival analysis 
Univariate Cox regressions were computed for survival variables (OS or PFI) and 
sample characteristics: age at diagnosis, gender, tumour stage, tumour grade, total TERT 
expression, TERT isoform expressions and percentages (Appendix D). Univariate Cox 
regressions were also computed between survival variables (OS and PFI) and the tumour 
subtypes defined in Table 3 (Appendix D). Characteristics (clinical or expression based) 
reaching significance (p-value <  0.05) in univariate Cox regressions were recomputed 
together in a multivariate Cox regression. For multivariate Cox regressions, if cancer 
subtype showed a significant difference in survival/progression it was used instead of any 
other clinical variables. However, if cancer subtype was not available or not significant, 
then all other significant clinical variables were used. For categorical variables the 
reference stratum to which other strata were compared for statistical significance, was 
chosen by the stratum with the lowest hazard ratio (HR). Multivariate Cox regressions 
were also computed in a mutually exclusive manner between TERT expression variables 
and TERT isoform percentage variables.  
If TERT expression/percentage variables remained significant in multivariate Cox 
regressions, then Cox model assumptions were checked. Schoenfeld residuals were 
checked for time independence. The Schoenfeld residual is a weighted average of each 
covariate, weighted by each samples likelihood of an event occurring over time. Plotted 
against time, the Schoenfeld residuals should show a random distribution pattern. In the 
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event the Schoenfeld has a significant non-random patterning (i.e. test failed) for a 
categorical variable, samples were stratified by that categorical variable and Cox 
regressions were recomputed for each stratum. In addition, deviance residuals were 
examined for symmetry to identify influential observations.  
In the event there were no significant co-variates relating to OS or PFI, a Kaplan-
Meier plot was generated by stratifying the significant TERT variable at the median 
value. In the event multiple TERT-based variables were significant from univariate Cox 
regressions, then multivariate Cox regressions were computed mutually exclusive 
between isoform expression variables and isoform percentage variables. Those with 
persisting significance had a Kaplan-Meier plot was generated by stratifying at the 
median value.  
Multivariate Cox regressions that passed Cox assumption tests were computed for 
hazard ratios and 95% confidence interval. Hazard ratios greater than one indicate an 
increased probability of an event (i.e. death or progression for OS and PFI, respectively), 
whereas hazard ratios less than one indicate the decreased probability of an event.  
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Chapter 3 – Results 
3.1. TERT expression analyses 
3.1.1. Total TERT expression  
 Overall TERT gene expression was low, with mean expression values less than 
one TPM in every cancer type except thymic tumours (Figure 7). Among the 33 TCGA 
cancer types, eight had a large fraction (at least 1/4 of samples), expressing zero TERT 
(Figure 8). Specifically, these TERT-negative cancer types were related to adrenal, 
kidney, thyroid, brain or soft tissue origin. The lowest TERT expression was in the 
Pheochromocytoma and Paraganglioma (PCPG) tumour type with a mean expression of 
0.03 TPM (Figure 7) in TERT-positive samples. PCPG tumours had over 75% TERT-
negative samples (Figure 8). On the other hand, the highest TERT expression was in 
Thymoma (THYM), with a mean expression about 125 times higher (Figure 7) and all 
samples expressed TERT at some level (Figure 8).  
Among the 19 GTEx normal tissue types, the majority (12/19) had at least 50% of 
samples expressing zero TERT (Figure 9). The remaining seven tissues expressing TERT 
in more than half their respective samples were blood, brain, colon, esophageal, skin, 
stomach and testicular tissues. Similarly, gastrointestinal and testicular tissues had 
elevated TERT expression, but the only normal tissue type with mean TERT expression 
above one TPM was testicular tissue (Figure 7). Interestingly, while brain cortical 
samples were used for normal comparisons to gliomas, the highest TERT expression 
among brain tissue subtypes were in basal ganglia structures (caudate, nucleus 
accumbens, putamen and substantia nigra) (Figure 10). To confirm the tumorigenic-
related increase in TERT expression between normal and neoplastic tissue, each tumor 
type was compared to matched normal tissue. 
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Figure 7. Variable total TERT expression observed across TCGA tumour types and 
GTEx normal tissue types. Total TERT expression across TCGA tumours shows tumour-
specific expression. Total TERT expression across GTEx normal tissue types shows 
majority have low expression except for gastrointestinal and testicular tissue types. Box 
plots boxes denote the inter-quartile range as well as a bolded line representing the median. 
Extending from the boxes are minimum and maximum lines calculated from 1.5 times the 
interquartile range. Points outside this range are considered outliers. Within each box is a 
red point signifying the mean, as well as, lines extending from this point representing a 
95% confidence interval. Expression values in transcript per million (TPM) were 
transformed by a log2(TPM + 0.001) equation. Horizontal line at y = 0 indicates 1 TPM.  
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Figure 8. Most TCGA tumour types have the majority of samples expressing TERT. 
Stacked bar plot summarizing the frequency of TERT-negative samples in each cancer 
type. Blue colour representing TERT-negative samples and gray representing TERT-
positive samples.  
 
 
 
 
Figure 9. Most GTEx normal tissue types have the majority of samples not expressing 
TERT. Stacked bar plot summarizing the frequency of TERT-negative samples in each 
cancer type. Blue colour representing TERT-negative samples and gray representing 
TERT-positive samples. 
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Figure 10. Total TERT expression is highest in basal ganglia brain structures in 
normal (GTEx) tissues. Total TERT expression in log10(TPM+1) scale, across normal 
human brain tissue subtypes. Expression values are shown in TPM, calculated from a gene 
model with isoforms collapsed to a single gene. No other normalization steps have been 
applied. Box plots are shown as median and 25th and 75th percentiles; points are displayed 
as outliers if they are above or below 1.5 times the interquartile range. Made using the 
GTEx portal (https://gtexportal.org/).  
 
 
From a total 19 normal-tumour comparisons, 13 had significantly higher 
(Bonferroni adjusted p < 0.000175) TERT expression in tumour samples (Figure 11). 
Adrenal, colon, brain lower grade glioma, prostate and thyroid cancers showed no 
significant difference. Testicular tissue showed significantly lower TERT expression in 
tumour samples.  
 
 
 40 
 
 
Figure 11. Total TERT expression is significantly higher in most tumour samples 
compared to matched normal tissue. Total TERT expression was significantly greater in 
tumour samples for 13/19 comparisons and significantly lower in testicular tumors. Box 
plots boxes denote the inter-quartile range as well as a bolded line representing the median. 
Extending from the boxes are minimum and maximum lines calculated from 1.5 times the 
interquartile range. Points outside this range are considered outliers. Within each box is a 
red point signifying the mean, as well as, lines extending from this point representing a 
95% confidence interval. Mean values are presented under each box. Transcript per million 
(TPM) values were transformed by a log2(TPM + 0.001) equation. A Wilcoxon rank sum 
test (also known as the Mann-Whitney U-test) was performed with a Bonferroni corrected 
p-value set at < 0.000175 (0.05/285 comparisons) to determine significance. If significant, 
the boxplot was given a red border. 
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3.1.2. TERT isoform expression  
Most (19/33) tumour types expressed all seven isoforms, 11/33 expressed six 
isoforms and 3/33 expressed five isoforms. In contrast, some normal tissue types only 
expressed 2/7 isoforms (adrenal), 3/7 isoforms (liver) or 4/7 isoforms (ovary, pancreas). 
Neoplastic samples primarily expressed FL-TERT, TERT_238.6 and TERT_656.1.  The 
primary isoform expressed across all normal tissue types was TERT_238.6, followed by 
FL-TERT in 11/16 tissue types. From the remaining 5/16, adrenal tissue and hepatic tissue 
did not express FL-TERT.  
PCA biplots across cancer types, with some exceptions, showed that FL-TERT, 
TERT_238.6 and TERT_656.1 had strong positive correlations with each other (Figure 12). 
These three highly expressed isoforms, with some exceptions, had weak or no correlations 
with ß-TERT and strong negative correlations with γ-TERT. This same trend was not 
observed across normal tissues. However, normal tissue types with greater total TERT 
expression, such testicular tissue and the gastrointestinal tract tissues, closely approximated 
what was observed in tumour tissues (Figure 12).  
 
 
 
ACC Adrenal 
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Figure 12. Normal tissue types with greater total TERT expression approximate the 
isoform correlation framework observed in tumour tissues. PCA biplots for each 
tumour and normal tissue type are plotted using the first two principal components and 
show the loading of each TERT isoform variable (arrow) expressed. The arrow length 
approximates the variance of the variable. The angle between arrows approximates the 
correlations between variables. Such that parallel arrows in the same direction have positive 
correlations, perpendicular arrows have no/weak correlations, and parallel arrows in the 
opposite direction have negative correlations.  
  
 
 
 
DLBC LAML Blood 
GBM LGG Brain 
LUAD LUSC Lung 
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Out of 19 normal-tumour comparisons, 16 had significantly increased (Bonferroni 
adjusted p < 0.000175) FL-TERT expression in tumour samples (Table 4). Similarly, FL-
TERT isoform percentage was significantly higher in 17/19 comparisons (Table 5). While 
7/8 significant differences observed for TERT_238.6 expression were increases in tumour 
tissue (Table 4), the opposite was observed with TERT_238.6 isoform percentage where 
7/8 significant differences observed were increases in normal tissue (Table 5). The 
exceptions in each of these cases of normal testicular tissue having significantly increased 
TERT_238.6 expression and lung adenocarcinomas having significantly increased 
TERT_238.6 isoform percentage. TERT_656.1 expression and isoform percentage were 
significantly higher in tumour tissues, with the exception of testicular tumours that 
showed significantly lower expression and isoform percentage (Tables 4 & 5). Only 
stomach adenocarcinoma (STAD) had significantly higher ß-TERT expression and 
isoform percentage than matched normal tissue (Table 4). Meanwhile, ovarian and 
pancreatic normal tissue had a significantly higher ß-TERT isoform percentage. LAML 
and STAD has significantly increased αßγ-TERT expression and isoform percentage than 
in matched normal tissue (Tables 4 & 5). There were no significant differences for γ-
TERT. Finally, LAML and ESCA had significantly higher TERT_877.1 expression and 
isoform percentage, while STAD only had significantly increased TERT_877.1 
expression (Tables 4 & 5). There were no other significant differences in expression or 
isoform percentage between normal and tumour samples.  
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Table 4. Sample type with significantly higher isoform expression across tissue types. 
  Expression* 
Normal Tumour FL-TERT TERT_238.6 TERT_656.1 ß-TERT αßγ-TERT γ-TERT TERT_877.1 
Adrenal ACC         
Breast BRCA Tumour       
Blood DLBC Tumour Tumour Tumour     
 LAML Tumour Tumour Tumour  Tumour  Tumour 
Brain GBM Tumour Tumour Tumour     
 LGG Tumour  Tumour     
Colon COAD Tumour       
Esophagus ESCA Tumour  Tumour    Tumour 
Liver LIHC Tumour Tumour      
Lung LUAD Tumour Tumour Tumour     
 LUSC Tumour Tumour Tumour     
Ovary OV Tumour       
Pancreas PAAD Tumour       
Prostate PRAD Tumour       
Skin SKCM Tumour  Tumour     
Stomach STAD Tumour  Tumour Tumour Tumour  Tumour 
Testicular TGCT   Normal Normal     
Thyroid THCA         
Uterus UCEC Tumour Tumour      
*”Tumour” indicates the tumour tissue had a significantly higher isoform expression. “Normal” indicates the 
normal tissue had a significantly higher isoform expression. Blank spots indicate no significant difference 
was observed. Significance was determined using a Wilcoxon rank sum test (also known as the Mann-
Whitney U-test) with a Bonferroni corrected p-value set at < 0.000175 (0.05/285 comparisons).  
 
 
 
Table 5. Sample type with significantly higher isoform percentage across tissue types. 
  Isoform Percentage* 
Normal Tumour FL-TERT TERT_238.6 TERT_656.1 ß-TERT αßγ-TERT γ-TERT TERT_877.1 
Adrenal ACC         
Breast BRCA Tumour       
Blood DLBC Tumour  Tumour     
 LAML Tumour Normal Tumour  Tumour  Tumour 
Brain GBM Tumour Normal Tumour     
 LGG Tumour Normal Tumour     
Colon COAD Tumour Normal      
Esophagus ESCA Tumour Normal Tumour    Tumour 
Liver LIHC Tumour       
Lung LUAD Tumour Normal Tumour     
 LUSC Tumour Tumour Tumour     
Ovary OV Tumour   Normal    
Pancreas PAAD Tumour   Normal    
Prostate PRAD         
Skin SKCM Tumour  Tumour     
Stomach STAD Tumour Normal  Tumour Tumour   
Testicular TGCT Tumour  Normal     
Thyroid THCA Tumour       
Uterus UCEC         
*”Tumour” indicates the tumour tissue had a significantly higher isoform percentage. “Normal” indicates the 
normal tissue had a significantly higher isoform percentage. Blank spots indicate no significant difference 
was observed. Significance was determined using a Wilcoxon rank sum test (also known as the Mann-
Whitney U-test) with a Bonferroni corrected p-value set at < 0.000175 (0.05/285 comparisons).  
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3.1.3 ß-Deletion splicing regulation factors  
 For each cancer type, samples were groups into FL-TERT expressing (isoform 
percentage > 0) and FL-TERT non-expressing (isoform percentage = 0). Comparing the 
expression of NOVA1 between these two groups, NOVA1 expression was significantly 
different (Bonferroni adjusted p < 0.00152) between FL-TERT groups in 3/33 cancer types 
(Figure 13). Specifically, in lung adenocarcinoma (LUAD) the FL- TERT expressing group 
had significantly higher NOVA1 expression. However, stomach adenocarcinoma (STAD) 
and breast invasive carcinoma (BRCA) had significantly higher NOVA1 expression in the 
FL-TERT non-expressing group. Comparing the expression of PTBP1 between these 
groups found significant differences in 10/33 cancer types, all of which had significantly 
higher PTBP1 expression in the FL-TERT expressing group (Figure 14).  
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Figure 13. NOVA1 expression is significantly higher in the FL-TERT expressing 
group of only LUAD. NOVA1 expression was significantly different between FL-TERT 
expressing groups in 3/33 cancer types. Box plots boxes denote the inter-quartile range as 
well as a bolded line representing the median. Extending from the boxes are minimum and 
maximum lines calculated from 1.5 times the interquartile range. Points outside this range 
are considered outliers. Within each box is a red point signifying the mean, as well as, lines 
extending from this point representing a 95% confidence interval. Mean values are 
presented under each box. Transcript per million (TPM) values were transformed by a 
log2(TPM + 0.001) equation. A Wilcoxon rank sum test (also known as the Mann-Whitney 
U-test) was performed with a Bonferroni corrected p-value set at < 0.00152 (0.05/33 
comparisons) to determine significance. If significant, the boxplot was given a red border. 
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Figure 14. PTBP1 expression is significantly higher in the FL-TERT expressing group 
of many cancer types. PTBP1 expression was significantly different between FL-TERT 
expressing groups in 10/33 cancer types. Box plots boxes denote the inter-quartile range as 
well as a bolded line representing the median. Extending from the boxes are minimum and 
maximum lines calculated from 1.5 times the interquartile range. Points outside this range 
are considered outliers. Within each box is a red point signifying the mean, as well as, lines 
extending from this point representing a 95% confidence interval. Mean values are 
presented under each box. Transcript per million (TPM) values were transformed by a 
log2(TPM + 0.001) equation. A Wilcoxon rank sum test (also known as the Mann-Whitney 
U-test) was performed with a Bonferroni corrected p-value set at < 0.00152 (0.05/33 
comparisons) to determine significance. If significant, the boxplot was given a red border. 
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3.2. TERT functional analyses 
3.2.1 Telomerase activity signature score correlation  
 Comparing signature score expression to TERT isoform percentages resulted in 
significant correlations (Bonferroni adjusted p < 0.000216) in 3/7 TERT isoforms. 
Specifically, these were present in FL-TERT, TERT_238.6, and TERT_656.1. There 
were 9/33 significant positive correlations for FL-TERT isoform percentage and signature 
score expression. Similarly, there were 2/33 significant positive correlations between 
TERT_656.1 isoform percentage and signature score expression. In contrast, there were 
14/33 significant negative correlations between TERT_238.6 isoform percentage and 
signature score expression (Figure 15). 
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Figure 15. Telomerase activity signature score correlates to increased FL-TERT 
isoform percentage but decreased TERT_238.6 isoform percentage. FL-TERT isoform 
percentage (significant in 9/33 cancer types) were all positive correlations. TERT_238.6 
isoform percentage had significant negative correlations in 14/33 cancer types and 
TERT_656.1 had significant positive correlations in 2/33 cancer types. ß-TERT, αßγ-TERT 
and γ-TERT isoform percentage had no significant correlations to signature score 
expression. Spearman correlations were computed, and significance determined using a 
Bonferroni corrected p-value of < 0.000216 (0.05/231). Correlations were highlighted with 
colour only if significant, blue indicating a significant positive correlation, red indicating a 
significant negative correlation. Spearman’s coefficients are displayed, and colour intensity 
also indicates the strength of correlation. Question marks (“?”) indicate no correlation could 
be computed between signature score and the respective TERT isoform. 
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3.2.2. Telomere length correlation 
 When compared to telomere lengths of matched controls, the tumour telomere 
length was shortened in most samples for every cancer type except TGCT, where 52% of 
samples had lengthened telomere lengths in tumours (Figure 16). From 31 cancer types, 
three had a significant (Bonferroni adjusted p < 0.000108) correlation between telomere 
length ratio and total TERT expression. Specifically, TGCT and THYM had positive 
correlations while SARC had a negative correlation (Figure 17). Only SARC had a 
significant correlation between FL-TERT expression and telomere length ratio (Figure 
18). No cancer types had a significant positive correlation between telomere length ratio 
and FL-TERT isoform percentage (Figure 19). With respect to the other six isoforms, 
there were no significant correlations with telomere length ratio (Appendix E.1 – E.10).  
 
Figure 16. Only testicular germ cell tumours have elongated telomeres in more  
than half their samples compared to normal telomere length. Stacked bar plot of 
percentages of tumour samples with elongated telomere length. Taking the log(tumour 
telomere length/control telomere length), if greater than zero would indicate telomere 
lengthening. Percentages are displayed, blue for elogated and gray for not. 
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Figure 17. Total TERT expression has no significant relationship to telomere length 
ratio in most cancer types. TGCT and THYM had significant positive correlations 
between total TERT expression and telomere length ratio, while SARC had a significant 
negative correlation. Telomere length ratios and total TERT expression were log10 and 
log2(TPM + 0.001) transformed, respectively. Scatter plots were fitted with a linear 
regression line and 95% confidence interval. Spearman correlations were computed, and 
significance determined using a Bonferroni corrected p-value of < 0.000108 (0.05/465). 
Significant correlations are highlighted with a red border. 
R = 0.04, p = 0.78
R = 0.25, p = 0.11
R = -0.34, p = 0.0021
R = -0.12, p = 0.21
R = 0.071, p = 0.18
R = 0.1, p = 0.43
R = 0.14, p = 0.0061
R = -0.066, p = 0.48
R = -0.17, p = 0.0033
R = -0.097, p = 0.56
R = 0.33, p = 4.6e−05
R = -0.049, p = 0.18
R = -0.085, p = 0.33
R = 0.13, p = 0.022
R = 0.016, p = 0.75
R = -0.0071, p = 0.93
R = 0.0057, p = 0.96
R = 0.074, p = 0.12
R = 0.0094, p = 0.85
R = 0.12, p = 0.31
R = 0.38, p = 5.1e−05
R = 0.055, p = 0.78
R = 1, p = 1
R = 0.12, p = 0.041
R = -0.45, p = 2.6e−06
R = -0.074, p = 0.82
R = 0.13, p = 0.044
R = -0.18, p = 0.18
R = 0.16, p = 0.29
R = 0.14, p = 0.17
R = 0.0024, p = 0.99
TCGA UVM
TCGA STAD TCGA TGCT TCGA THCA TCGA THYM TCGA UCEC TCGA UCS
TCGA PAAD TCGA PCPG TCGA PRAD TCGA READ TCGA SARC TCGA SKCM
TCGA KIRP TCGA LGG TCGA LIHC TCGA LUAD TCGA LUSC TCGA OV
TCGA DLBC TCGA ESCA TCGA GBM TCGA HNSC TCGA KICH TCGA KIRC
TCGA ACC TCGA BLCA TCGA BRCA TCGA CESC TCGA CHOL TCGA COAD
−1.5−1.0−0.5 0.0
−5.0−2.50.0 2.5 5.0−1 0 1 2 −2 0 2 −2 −1 0 1−1.0−0.50.0 0.5 1.0−5.0−2.5 0.0 2.5
−2.5 0.0 2.5 −1.0 −0.5 0.0 0.5 −4 −2 0 2 −1 0 1 2−2.5 0.0 2.5 −3 −2 −1 0 1
−2 −1 0 1 2 3 −2 0 2 4 −2 −1 0 1 2 −5.0−2.50.0 2.5 5.0 −4 −2 0 2 −1 0 1
−1.0−0.50.0 0.5 −4 −2 0 2 −5.0−2.5 0.0 2.5 −2.5 0.0 2.5 −0.5 −0.4 −0.3−4 −2 0 2
−3−2−1 0 1 2 −2 0 2 −2 0 2 −4 −2 0 2 −2 −1 0 1 −2 0 2
−10
−5
0
5
−10
−5
0
5
−10
−5
0
5
−10
−5
0
5
−10
−5
0
5
−10
−5
0
5
log(Tumour TL/Control TL)
To
ta
l T
ER
T 
[lo
g2
(T
PM
 +
 0
.0
01
)]
 57 
 
Figure 18. FL-TERT isoform expression has a significant negative correlation only 
with telomere length ratio in sarcomas. Only SARC had significant correlation which 
was negative. Telomere length ratios and FL-TERT expression were log10 and log2(TPM + 
0.001) transformed, respectively. Scatter plots were fitted with a linear regression line and 
95% confidence interval. Spearman correlations were computed, and significance 
determined using a Bonferroni corrected p-value of < 0.000108 (0.05/465). Significant 
correlations are highlighted with a red border. 
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Figure 19. FL-TERT isoform percentage has no significant negative correlation with 
telomere length ratio. There were no significant correlations with FL-TERT isoform 
percentage. Telomere length ratios and FL-TERT isoform percentage were log10 and 
log2(TPM + 0.001) transformed, respectively. Scatter plots were fitted with a linear 
regression line and 95% confidence interval. Spearman correlations were computed, and 
significance determined using a Bonferroni corrected p-value of < 0.000108 (0.05/465). 
Significant correlations are highlighted with a red border. 
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3.3. UMAP clustering using TERT isoform expression patterns 
 Projecting TCGA samples using TERT isoform expression and labelling tumour 
type showed nosier clustering/more smaller clusters (Figure 20a) – than when clustering 
using TERT isoform percentage (Figure 20b). Further evaluating the three major clusters 
from TERT isoform percentage found the top cluster had ~100% FL-TERT expression, the 
right cluster had ~100% TERT_238.6 expression and the centre cluster followed a 
“conventional” tumour TERT isoform expression magnitude pattern of predominantly FL-
TERT and TERT_238.6 expression, followed by TERT_656.1, ß-TERT, αßγ-TERT, γ-
TERT and lastly TERT_877.1 (Figure 20b). PCPG tumours were enriched in the right 
cluster, comprising 62% of samples. The largest enrichment in the top cluster was UVM 
with 23% of samples comprising this group.  
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Figure 20. TERT isoform percentage- but not expression-based clustering shows three 
distinct clusters. a) Isoform expression-based clustering produced many small clusters. b) 
Isoform percentage-based clustering produced three major clusters: “conventional” tumour 
TERT isoform expression pattern, predominantly FL-TERT expression and predominantly 
TERT_238.6 expression. Each point represents one sample; colour labeled by tumour type. 
Parameters: Manhattan distance, 32 neighbours and 3 components.  
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3.4. Tumour subtype specific differences in TERT isoform expression patterns  
 Comparing the TERT isoform expression and percentage, total TERT expression 
and telomere length ratio between cancer subtypes found at least one significant 
difference (p < 0.05) in 14/29 tumour types (Table 6). LIHC (TCGA Network, 2017a) 
and GBM/LGG (Ceccarelli et al., 2016) subtype-dependent differences in TERT 
expression are discussed in their respective subtype characterization papers. The 
remaining 11/14 cancer subtype differences are outlined with potential subtype specific 
TERT expression altering mechanisms (Table 7). 
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Table 6. Cancer types with significant subtype-specific differences in TERT 
expression patterns or telomere length ratio 
 
*Indicates significant difference (S.D.) in TERT isoform expression, percentage, total 
TERT expression or telomere length ratio between cancer subtypes 
 
 
 
 
 
 
 
 
S.D. CANCER TYPE SUBTYPES 
 ACC CIMP-high, CIMP-intermediate, CIMP-low 
* BLCA Basal Squamous, Luminal, Luminal Infiltrated, Luminal Papillary, 
Neuronal 
* BRCA C1, C2, C3, C4, C5 
 CESC C1, C2, C3, C4, C5 
 CHOL ECC, IDH, METH2, METH3 
* COAD  CIN, GS, HM-SNV, MSI 
* ESCA  CIN, GS, HM-SNV, MSI 
* GBM Classic-like, G-CIMP-high, G-CIMP-low, LGm6-GBM, 
Mesenchymal-like 
* HNSC Atypical, Basal, Classical, Mesenchymal 
 KICH Eosinophilic, Classic 
 KIRC C1, C2, C3, C4 
 KIRP C1, C2a, C2b, C2c-CIMP 
* LGG Classic-like, Codel, G-CIMP-high, G-CIMP-low, Mesenchymal-
like, PA-like 
* LIHC C1, C2, C3 
* LUAD C1, C2, C3, C4, C5, C6 
* LUSC Basal, Classical, Primitive, Secretory 
 OV C1, C2, C3, C4, C5 
 PAAD Basal, Classical 
 PCPG Cortical, Kinase, Pseudohypoxia, Wnt-altered 
 PRAD ERG, ETV1, ETV4, FLI1, FOXA1, IDH1, SPOP, Other 
 READ  CIN, GS, HM-SNV, MSI 
* SARC C1, C2, C3, C4, C5 
 SKCM BRAF Hotspot Mutants, NF1 Any Mutants, RAS Hotspot Mutants, 
Triple WT 
* STAD  CIN, EBV, GS, HM-SNV, MSI 
* TGCT Seminoma, Embryonal, Yolk Sac, Teratoma, Mixed 
 THCA C1, C2, C3, C4, C5 
* THYM C1, C2, C3, C4 
 UCEC  C1, C2, C3, C4, C5 
 UCS  C1, C2, C3, C4, C5 
 UVM C1, C2, C3, C4 
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Table 7. Cancer subtypes with significantly different TERT expression patterns or 
telomere length ratio and evidence-based rationale for the differences 
  
SUBTYPE CATEGORY  †SUBTYPE 
CHARACTERIZATION  
RATIONALE OR 
HYPOTHESIS 
BLCA Basal 
Squamous 
Increased FL-
TERT Expression 
High expression of stem-
like markers. 
Cellular potency is 
positively related to TERT 
expression and TA1. 
   
Neuronal  Increased αßγ-
TERT Expression 
and Isoform 
Percentage  
High frequency of RB1 
mutations and worst 
survival outcome. 
N/A 
BRCA C1 Decreased TERT 
Expression and 
TL Ratio 
Enriched for one or more 
positive hormone receptors 
and had improved survival. 
ER promotes TERT 
expression by binding to 
TERT promoter4. However, 
ER expression is inversely 
correlated with TERT 
expression5. Possible 
negative feedback control 
system. 
  
COAD 
STAD 
CIN Increased TERT 
Expression 
Predominated by tumours 
at anatomical extremes of 
GI tract. Low mutational 
density but chromosomal 
instability and aneuploidy.  
Aneuploidy is associated 
with telomere deficiency6 
but increased TERT 
expression and TA7. 
Telomere replication stress 
induced by aneuploidy can 
be alleviated by TA8. 
COAD 
STAD 
GS Decreased TERT 
Expression 
Low mutational density 
and genome stability. 
HNSC Basal Decreased TERT, 
FL-TERT 
Expressions and 
TL Ratio 
Enriched by NOTCH1 
inactivation, decreased 
SOX2 expression and 
HRAS-CASP8 co-
mutations. 
NOTCH1 activation results 
in increased TERT 
expression and TA in dental 
follicle cells9. Therefore, 
NOTCH1 inactivation may 
result in decreased TERT 
expression and TA.  
  
LUAD C2 Increased FL-
TERT Expression 
Exclusively PP tumours. 
Enriched for KRAS 
mutations and STK11 
inactivation.  
KRAS mutations increases 
TERT expression, TA and 
TL in immortalized 
bronchial epithelial and lung 
adenocarcinoma cells10. 
KRAS enhances TERT 
transcription through RAS-
MEK pathway. 
  
LUSC Primitive Increased FL-
TERT Isoform 
Percentage 
  
Limited differentiating 
qualities. 
N/A 
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SARC C1 Decreased TERT 
Expression 
Primarily LMS tumours 
with higher frequency of 
RB1 mutations. Unlike 
UPS and MFS subtypes, 
LMS found no association 
between telomere 
lengthening and ATRX 
alterations.  
  
While ALT is typically 
associated with loss of 
ATRX/DAXX2, studies have 
found ALT tumours with 
RB1 mutations mutually 
exclusive of ATRX/DAXX 
mutations3. UPS and MFS 
employ ALT via ATRX 
alterations, but LMS does so 
through loss of RB1. 
   
C2 Increased TERT 
Expression 
Primarily DDLPS 
tumours. Sub-cluster of 
DDLPS tumours based on 
somatic copy number 
alteration found to have 
worse survival and TERT 
amplification. 
  
DDLPS tumours have 
increased TERT expression 
due to TERT amplification 
events. 
 
C4 Increased TERT 
Expression 
Exclusively SS tumours. 
High FGFR3 and miR-183 
expression and PDE4A 
promoter methylation. 
  
No known associations with 
TERT. 
TGCT Embryonal  Increased TERT 
Expression 
Subcategory of NSE 
tumours which arise from 
early gonadal stem cells 
and exhibit gonadal 
morphology. 
NSE tumours have increased 
TERT expression, TL and 
stemness gene expression 
than SE tumours11. TERT 
expression and TA decline 
with differentiation status of 
TGCTs12.   
  
THYM C1, C3 Increased TERT 
Expression 
Higher lymphocyte 
content. 
Normal lymphocytes have 
endogenous TERT 
expression13. 
 
†Subtype characterizations taken from papers outlined in Table 3 
1(Wright et al., 1996), 2(Heaphy et al., 2011b; Ramamoorthy & Smith, 2015), 3(Barthel et al., 2017; 
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Sieverling et al., 2020), 4(Ramlee 
et al., 2016), 5(Long et al., 2016), 6(Blasco et al., 1997; Lee et al., 1998; Niida et al., 1998; Plentz et al., 2005; 
Treff et al., 2011; Suraweera et al., 2016), 7(Fang et al., 2017), 8(Meena et al., 2015), 9(Chen et al., 2013), 
10(Liu et al., 2017a), 11(Sun et al., 2019), 12(Schrader et al., 2002), 13(Hiyama et al., 2001) 
TA = telomerase activity; TL = telomere length; ATRX = α-thalassaemia/mental retardation syndrome X-
linked; DAXX = death domain-associated protein; ALT = alternative lengthening of telomeres; RB1 = 
retinoblastoma protein; ER = estrogen receptor; GI = gastrointestinal; PP = proximal proliferative; LMS = 
smooth muscle differentiated leiomyosarcoma; UPS = undifferentiated pleomorphic sarcoma; MFS = 
myxofibrosarcoma; DDPLS = dedifferentiated liposarcoma; SS = synovial sarcoma; SE = seminoma; NSE = 
non-seminoma 
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3.5. Prognostic impact of TERT isoform expression patterns 
3.5.1. Overall survival (OS) 
 From 29 cancer types that were suitable for OS analysis, six cancer types (COAD, 
ESCA, HNSC, KIRP, READ and SKCM) had significant multivariate Cox regressions 
with at least one clinical/subtype variable and at least one TERT-based variable. From 
these, only KIRP and SKCM passed multivariate Cox regression assumptions of time-
independence (Schoenfeld residuals) and non-influential outliers (deviance residuals). 
KIRP OS was significantly (p < 0.05) improved (HR = 0.96) by diagnosis age but poorer 
by increased tumour stage (HR = 4.08) and TERT_238.6 expression (HR = 1.28). SKCM 
OS was significantly poorer by increased tumour stage (HR = 3.4) and αßγ-TERT 
isoform percentage (HR =  1.5) (Table 8). The remaining four cancer types failed the 
assumptions required for multivariate Cox regressions, so they were stratified by their 
respective clinical/subtype variable before univariate Cox regressions were recomputed 
for significant TERT-based variables (Table 8). 
 COAD OS was significantly poorer by increased total TERT expression (HR = 
1.5) only in stage 2 tumours. Stratifying ESCA by tumour stage found no significant 
results but stage 2 tumours were closest to significance (p = 0.099) for reduced survival 
(HR = 1.2) with increased TERT_656.1 isoform percentage. HNSC OS was significantly 
improved by total TERT expression (HR = 0.81) only in the atypical subtype. READ OS 
was significantly improved by FL-TERT isoform percentage (HR = 0.63) only in older 
patients (Table 8).  
Another five cancer types (CHOL, LUSC, MESO, PRAD and SARC) had 
significant OS outcomes based on TERT variables only (Figure 21).  
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Table 8. Overall survival is significantly related to TERT isoforms after adjusting for 
clinical co-variates in KIRP and SKCM, and after co-variate stratification in COAD, 
HNSC, and READ.  
  Overall Survival 
Tumour Group Covariate* HR (95% CI) P Value† 
KIRP (N=66) Diagnosis Age 0.96 (0.93 - 1.0) 0.037 
 Stage 4.08 (1.79 - 9.3) <0.001 
 
 
TERT_238.6 Expression 
(N = 50/66) 
1.28 (1.06 - 1.6) 0.012 
 
SKCM (N=53) 
Stage 3.4 (1.2 - 9.3) 0.018 
 αßγ-TERT Isoform %  
(N = 4/53) 
1.5 (1.1 - 2.2) 0.016 
COAD Stage II (N=99) Total TERT 1.5 (1.1 - 2.2) 0.02 
ESCA Stage II (N=21) 
 
TERT_656.1 Isoform % 
(N = 10/21) 
1.2 (0.96 - 1.6) 0.099 
 
HNSC Atypical Subtype 
(N=47) 
Total TERT 0.81 (0.67 - 0.99) 0.036 
 
READ Age > Median 
(N=61) 
FL-TERT Isoform %  
(N = 59/61) 
0.63 (0.45 - 0.87) 0.005 
 
*N-values showed in this “co-variate” column are those that expressed the isoform of interest from the total 
tumour group-specific sample size. 
†P-values < 0.05 was deemed significant. 
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Figure 21. CHOL, PRAD, SARC and MESO overall survival (OS) is significantly 
related to TERT isoforms but not clinical co-variates. a) CHOL OS is significantly 
poorer by increased TERT_656.1 expression. 8/30 CHOL samples expressed TERT_656.1. 
b) LUSC OS is not significantly affected by TERT_238.6 isoform percentage. c) PRAD 
OS is significantly poorer by increased FL-TERT expression. 212/309 PRAD samples 
expressed FL-TERT. d) SARC OS is significantly poorer by TERT_656.1 isoform 
percentage. 23/85 SARC samples expressed TERT_656.1 e) SARC OS is significantly 
poorer by increased TERT expression. f) MESO OS is not significantly affected by TERT 
expression. g) MESO OS is significantly poorer by increased ß-TERT expression. 7/82 
MESO samples expressed ß-TERT. h) MESO OS is significantly poorer by increased ß-
TERT isoform percentage. 7/82 MESO samples expressed ß-TERT i) MESO OS is 
significantly poorer by increased FL-TERT expression. 52/82 MESO samples expressed 
FL-TERT. j) MESO OS is not significantly affected by FL-TERT isoform percentage. 
52/82 MESO samples expressed FL-TERT. Groups were stratified based on median 
expression/isoform percentage. Survival curves have 95% confidence interval and survival 
median dotted line. Y-axis shows survival probability. X-axis shows days to death event.   
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3.5.2. Progression-free interval (PFI) 
From 31 cancer types that were suitable for PFI analysis, seven cancer types 
(COAD, KIRC, KIRP, OV, READ, STAD and UCEC) had significant multivariate Cox 
regressions with at least one clinical/cancer subtype variable and at least one TERT-based 
variable. From these, only KIRP passed multivariate Cox regression assumptions of time-
independence (Schoenfeld residuals) and non-influential outliers (deviance residuals). 
KIRP PFI was significantly (p < 0.05) affected by tumour subtype, specifically Cluster 1 
having the best PFI. After adjusting for tumour subtype, KIRP PFI was significantly 
poorer by increased TERT_238.6 expression (HR = 1.4), TERT_656.1 expression (HR = 
1.2), TERT_656.1 isoform percentage (HR = 1.3) and total TERT expression (HR = 1.6) 
(Table 9). The remaining cancer types failed the assumptions required for multivariate 
Cox regressions, so they were stratified by their respective clinical/subtype variables 
before Cox regressions were recomputed (Table 9). 
 COAD PFI was significantly poorer by increased TERT_656.1 expression (HR = 
1.2) only in stage 2 tumours. KIRC PFI was significantly poorer by increased αßγ-TERT 
expression (HR = 1.7) and isoform percentage (HR = 1.4) only in cluster 1. KIRC PFI 
was also significantly poorer by increased αßγ-TERT isoform percentage (HR = 1.5) only 
in cluster 2. Stratifying STAD by gender and tumour stage found no significant result but 
female stage 3 tumours closest to significance (p = 0.06) for improved PFI with increased 
αßγ-TERT expression (HR = 0.75)  and isoform percentage (HR = 0.64). UCEC PFI was 
significantly improved by increased TERT expression (HR = 0.76) only in cluster 4 
(Table 9).  
Another five cancer types (OV, THCA, MESO, SARC, and THYM) had 
significant PFI outcomes based on TERT variables only (Figure 22). OV PFI was 
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significantly improved by increased γ-TERT expression (HR = 0.84) and isoform 
percentage (HR = 0.84). However, both γ-TERT variables failed the Cox model 
assumption of time-independence (Schoenfeld residuals). Therefore, using Kaplan-Meier 
plots showed high groups for both γ-TERT expression and isoform percentage had 
significantly improved PFI (Figure 22). THCA PFI was significantly affected by tumour 
subtype in univariate Cox regression, but not in multivariate Cox regression with 
significant TERT-based variables. Therefore, using Kaplan-Meier plots showed the low 
groups for FL-TERT isoform percentage, αßγ-TERT expression and isoform percentage 
all had significantly improved PFI (Figure 22).  
 
Table 9. Progression-free interval is significantly related to TERT isoforms after 
adjusting for clinical co-variates in KIRP, and after co-variate stratification in 
COAD, KIRC, and UCEC.  
  Progression Free Interval 
Tumour Group Covariate* HR (95% CI) P Value† 
KIRP (N=66) 
TERT_238.6 Expression 
(N = 47/66) 
1.4 (1.1 - 1.7) 0.003 
 
 
TERT_656.1 Expression 
(N = 8/66) 
1.2 (1.0 - 1.4) 0.027 
 
 
TERT_656.1 Isoform % 
(N = 8/66) 
1.3 (1.03 - 1.5) 0.023 
  
Total TERT 
1.6 (1.2 - 2.1) <0.001 
COAD Stage II (N=99) 
 
TERT_656.1 Expression 
(N = 51/99) 
1.2 (1 - 1.3) 0.013 
KIRC Cluster 1 (N=103) 
 
αßγ-TERT Expression   
(N = 4/103) 
1.7 (1.2 - 2.3) <0.001 
 
 
αßγ-TERT Isoform %  
(N = 4/103) 
1.4 (1.1 - 1.8) 0.006 
KIRC Cluster 2 (N=69) 
 
αßγ-TERT Isoform %  
(N = 2/69) 
1.5 (1.1 - 1.9) 0.003 
UCEC Cluster 4 (N=24) Total TERT 0.76 (0.59 - 0.97) 0.025 
*N-values showed in this “co-variate” column are those that expressed the isoform of interest from the total 
tumour group-specific sample size. 
†P-values < 0.05 was deemed significant. 
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Figure 22. OV, THCA, SARC and MESO progression-free interval (PFI) is 
significantly related to TERT isoforms but not clinical co-variates. a) OV PFI is 
significantly poorer by increased γ-TERT expression. 16/268 OV samples expressed γ-
TERT. b) OV PFI is significantly poorer by increased γ-TERT isoform percentage. 16/268 
OV samples expressed γ-TERT. c) THCA PFI is significantly poorer by increased αßγ-
TERT expression. 9/117 THCA samples expressed αßγ-TERT. d) THCA PFI is 
significantly poorer by increased αßγ-TERT isoform percentage. 9/117 THCA samples 
expressed αßγ-TERT.  e) THCA PFI is significantly poorer by increased FL-TERT isoform 
percentage. 57/117 THCA samples expressed FL-TERT.  g) MESO PFI is significantly 
poorer by increased ß-TERT expression. 7/82 MESO samples expressed ß-TERT. h) 
MESO PFI is significantly poorer by increased ß-TERT isoform percentage. 7/82 MESO 
samples expressed ß-TERT i) THYM PFI is not significantly affected by TERT expression. 
Groups were stratified based on median expression/isoform percentage. Survival curves 
have 95% confidence interval and survival median dotted line. Y-axis shows survival 
probability. X-axis shows days to progression event.   
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3.6. Cancer cell line TERT isoform expression patterns  
Primary tumour TERT isoform expression patterns were more like some related-
origin cancer cell lines (Table 10), but distinct from others (Appendix F). If available, TERT 
promoter mutational status was also noted.  
 
Table 10. Cancer cell lines that clustered closest to their related tumour type based on 
TERT isoform expression pattern  
  
TUMOUR 
TYPE 
CELL LINE 
BILIARY TRACT CHOL HUCCT1, SNU869 
  
HAEMATOPOIETIC & 
LYMPHOID TISSUE 
LAML OCIAML5 
DLBC SUPM2, KMH2, HL60, RS411, LOUCY  
  
CENTRAL NERVOUS 
SYSTEM & AUTONOMIC 
GANGLIA 
LGG IOMMLEE 
GBM IOMMLEE 
PCPG LNZ308, DKMG 
  
BREAST BRCA JIMT1, BT549 
  
LARGE INTESTINE COAD CL11WT 
  
ENDOMETRIUM CESC JHUEM2 
UCS JHUEM2 
UCEC JHUEM7 
  
ESOPHAGUS ESCA TE11WT, KYSE510, KYSE410P, COLO680N  
  
KIDNEY KIRC CAKI1WT 
KIRP CAKI1WT 
KICH CAKI1WT 
  
LIVER LIHC HEPG2P, LI7 
  
LUNG LUAD NCIH2030WT, DMS152, NCIH727WT, MORCPR 
LUSC NCIH596WT, NCIH2228WT, NCIH1755WT, CORL47WT 
  
OVARY OV COV362WT, JHOM1, TOV112D, OVK18WT 
   
PANCREAS PAAD CAPAN1WT 
  
PLEURA MESO NCIH2052P, ISTMES2WT  
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PROSTATE PRAD PC3WT 
  
SKIN SKCM SKMEL1, SKMEL28P, HT144P, HS695TP 
   
SOFT TISSUE SARC EW8, CADOES1WT, RD  
UCS EW8, CADOES1WT, RD 
   
STOMACH STAD MKN7WT, IM95WT, OCUM1 
   
THYROID THCA TT2609C02 
  
URINARY TRACT BLCA UMUC2, CAL29  
WT Indicates wild-type TERT promoter status (Ghandi et al., 2019); P Indicates mutated TERT promoter status 
(Ghandi et al., 2019); No superscript indicates TERT promoter status was not profiled 
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Chapter 4 – Discussion 
4.1. Telomere maintenance mechanisms in neoplastic tissue 
In this thesis, I described the expression patterns of TERT isoforms across various 
tissue types in both normal and neoplastic states. As a group, neoplastic samples had a 
significantly higher total TERT expression than normal samples. Since ~90% of cells 
ultimately employ the telomerase mediated TMM (Kim et al., 1994; Shay & Bacchetti, 
1997), it is understandable as to why tumour samples generally had significantly 
increased TERT expression. However, there were five cancer types that did not fit this 
trend. ACC, COAD, LGG and THCA did not have a significant difference, and TGCT 
had a significantly lower TERT expression than normal tissue. From these, ACC and 
LGG did have significant p-values (p = 0.0015 and p = 0.0013, respectively) but were not 
significant after Bonferroni correction. It is possible these may be false negatives due to a 
stringent correction. Alternative methods to correct for multiple comparisons to mitigate 
false negatives are discussed in Section 5.2.3. The other three cancer types, COAD, 
THCA and TGCT may have tissue-specific reasons for either no difference or lower 
TERT expression compared to normal tissue, discussed in Section 4.2. 
Nonetheless, the mechanism by which TERT expression becomes amplified has 
been attributed to multiple molecular modalities. Barthel et al. showed using a subset of 
TCGA samples with complete molecular profiles, that 95% of TERT expressing samples 
had some form of either TERT alteration (42%) or promoter methylation (53%). 
Irrespective of alteration type, all TERT altered tumour groups (gene amplification, 
structural variant, promoter methylation or mutation) had significantly higher expression 
than tumours harbouring a wild-type TERT gene and promoter (Barthel et al., 2017).  
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The remaining ~10% of cancer cells are thought to employ the ALT mediated 
TMM (Heaphy et al., 2011a). In this study, samples expressing zero TERT were most 
predominantly found in adrenal, kidney, thyroid, brain and soft tissue cancers. ALT has 
been characterized as prevalent in tissues of mesenchymal origin, namely soft tissues, the 
central or peripheral nervous and neuroendocrine systems (Henson & Reddel, 2010; 
Reddel, 2014; Pickett & Reddel, 2015). In 2011, Heaphy et al. performed a 
comprehensive characterization of ~7000 samples including primary tumours from 94 
different cancer subtypes, benign tumour and normal tissue samples (Heaphy et al., 
2011a). They detected, markers of ALT in ~4% of primary tumours with the highest 
percentage of ALT tumours originating from central nervous system and soft tissue 
cancers. There were also cases of ALT in adrenal (3-14% depending on subtype), kidney 
(1-9% depending on subtype), paraganglia (13%) but not thyroid tumours. A more recent 
review found the prevalence of ALT at 11% and citied thyroid tumours using ALT in an 
average of 8% of tumours (Dilley & Greenberg, 2015). These results closely aligned with 
my findings of cancer types with more TERT-negative samples. 
The major events that occur during ALT, reviewed in detail by Zhang et al., are 
collapsing replication forks, formation of promyelocytic leukemia protein nuclear bodies 
and telomere break-induced repair (Zhang & Zou, 2020). I found the negative regulators 
of each major step to have significantly increased expression in TERT-positive solid 
primary tumours compared to TERT-negative (Appendix E.11). Furthermore, in my 
investigations of telomere length I found SARC to have significant negative correlations 
between tumour telomere length ratio and FL-TERT expression. This result is observed in 
mesenchymal sarcomas, where telomere attrition is negatively correlated to TERT 
expression (Chi et al., 2008). Cancer cells are widely accepted to have short telomeres 
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due to selection for telomerase reactivation occurring during crisis (stage M2). Once 
telomeres are substantially eroded, subsequent re-lengthening is thought to function in a 
maintenance capacity. This was confirmed in the TCGA dataset as 30/31 cancer types had 
most of their samples with telomeres shorter than those in matched normal tissues. 
Although, consistent with previous findings (Sung et al., 2020) SARC was among the 
cancer types with a larger portion of samples with elongated telomeres. Cancer cells 
utilizing ALT have comparatively longer telomeres (Sieverling et al., 2020). Therefore, in 
ALT predominant cancer types such as SARC, there is likely a determinative process for 
employing ALT-mediated telomere maintenance resulting in longer telomeres or 
telomerase-mediated telomere maintenance resulting in shorter telomeres. Interestingly, 
the classical notion that TMM decision fate is absolute has been challenged with evidence 
of both mechanisms coexisting in cancer cells, suggesting TMM fate can be dynamic and 
parallels the dynamics of epithelial-mesenchymal transitions (Gocha et al., 2013; Sung et 
al., 2020).  
With respect to ALT determination, loss-of-function mutations in α-
thalassaemia/mental retardation syndrome X-linked (ATRX), a chromatin remodelling 
protein, or its binding partner death domain-associated protein (DAXX) are commonly 
observed in ALT-positive tumours (Heaphy et al., 2011b; Ramamoorthy & Smith, 2015). 
Together, they aide the deposition of histone variant H3.3 into telomeres and while the 
resulting functions are unclear, ATRX/DAXX mutations are linked to telomere 
dysfunction (Dyer et al., 2017). Interestingly, Barthel et al. identified a subset of tumours 
that did not express TERT nor harboured mutations in ATRX/DAXX. In this subset, the 
tumour’s telomere length was positively correlated with TP53 and RB1 mutations. 
Similarly, the PCAWG Consortium found an ALT-phenotypic cluster had marked RB1 
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mutations and suggested, due to the mutual exclusivity of RB1 mutations with ATRX 
mutations and lack of DAXX mutations, that loss of RB1 could independently activate 
the ALT TMM pathway (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes 
Consortium, 2020). Supporting this theory, I found the LMS sarcoma subtype to have 
significantly decreased TERT expression and a higher frequency of RB1 mutations. 
Despite this study’s focus on TERT-positive tumours, ALT mediated telomere 
maintenance is a significant area of research as they often present with dire prognoses 
(Dilley & Greenberg, 2015).  
 
4.2. TERT expression in normal tissue 
Most normal tissues were predominantly TERT-negative, except for tissue types 
that have quick cell turnover times, namely colon, blood, stomach, skin, and esophageal 
tissues (Milo & Phillips, 2015). This finding has been corroborated, as normal human 
tissue types that are mitotically active, parallel to those mentioned above, have been 
found to have telomerase activity (Leão et al., 2018). Therefore, a conserved mechanism 
is employed by actively dividing cells to sustain TERT expression and facilitate 
telomerase activity. In addition to these tissue types, brain and testicular tissue were also 
increasingly TERT-positive. Interestingly, testicular tissue was the only tissue type to 
significantly increase total TERT expression in normal samples. TGCTs are histologically 
classified as seminoma (SE) or non-seminoma (NSE). While SE TGCTs arise from late 
gonadal stem cells, NSE TGCTs arise from early gonadal stem cells (Tu et al., 2002) and 
have poorer outcomes (Kobayashi et al., 2013). More specifically, NSE TGCTs can be 
histologically classified as embryonal, teratoma or yolk-sac tumors. A recent report by 
Sun et al. found NSE TGCTs to have increased TERT expression, telomere-related and 
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stemness gene expression and telomere lengthening compared to SE TGCTs (Sun et al., 
2019). However, they did not assess the differences between NSE TGCT tumour subtypes 
nor made comparisons to normal tissue. Stratifying by histological subtype, I found 
embryonal NSE TGCTs had the highest FL-TERT expression followed by normal 
testicular tissue and lowest expression in other NSE histological subtypes and SE TGCTs 
(Appendix E.12). Correspondingly, TERT expression and telomerase activity declines 
with differentiation status in TGCTs (Schrader et al., 2002). Signifying a pluripotent 
network that sustains telomerase mediated telomere maintenance but is withdrawn upon 
differentiation, resulting in reduced TERT expression, TA and TL (Teichroeb et al., 2016; 
Hannen & Bartsch, 2018).  
Colon and thyroid tissues were found to have no significant difference in TERT 
expression levels compared to matched tumour tissue. Among all normal tissue types, 
after testicular tissue, colon tissue had the highest total TERT expression. Moreover, at 2-
4 days, intestinal epithelial cells have the fastest cell turnover rate (Milo & Phillips, 
2015). Moreover, TERT promoter mutations are common in tissues that don’t have high 
rates of cell turnover (Chiba et al., 2015). Therefore, seeing as colon tissue has an 
endogenous high level of TERT expression, there may be other downstream mechanisms 
of TERT regulation, outside of increasing total expression, at play during tumorigenesis. 
Evidence for this at the level of splicing is clear as COAD had a significantly higher FL-
TERT isoform percentage than normal colon tissue. Similarly, while THCA showed no 
significant difference in total or FL-TERT expression, I observed a significantly increased 
FL-TERT isoform percentage in THCA compared to normal thyroid tissue. Moreover, 
THCA was among the tissue types with a greater proportion of TERT-negative samples, 
alluding to the utilization of ALT.  
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A study conducted by Hiyama et al. evaluating TERT expression and telomerase 
activity in various normal human tissues found both in skin (basal keratinocytes), 
tonsil/spleen/thyroid (lymphocytes), esophagus (basal cells), stomach (mucosal basal 
cells), small intestine (basal cells of villi), colon (basal cells of crypt), placenta 
(trophoblasts in chorionic villi), endometrium (basal cells) and testis 
(spermatocytes/spermatids) (Hiyama et al., 2001). These results align closely with my 
findings of normal tissues types with predominately TERT-positive samples, except for 
blood (not analyzed by Hiyama et al.) and brain tissue (found no expression or activity by 
Hiyama et al.). Normal blood leukocytes exhibit low levels of telomerase activity 
(Counter et al., 1995) and since GTEx blood samples were taken as whole blood, the 
lymphocytic TERT expression is also likely detected. Interestingly, I found ~95% of 
brain cortical samples were TERT-positive and had the fifth highest average of TERT 
expression among normal tissue types. 
Studies have outlined the importance of TERT expression in neural 
progenitor/stem cells for neural differentiation and survival using rodent models (Mattson 
et al., 2001). The expression and importance of TERT persisted in adult rodent brain 
structures such as the hippocampus and olfactory bulb, possibly due to enrichment of 
progenitor cells, where TERT-deficient mice had abnormal behaviours and olfaction (Lee 
et al., 2010; Liu et al., 2018b). Klapper et al. showed that while telomerase activity 
declines and becomes undetectable postnatally, TERT expression persists at low levels in 
adulthood in the rodent hippocampus, brainstem and cortex (Klapper et al., 2001). 
However, there are important species-dependent differences between human and rodent 
TERT. Notably, the rodent TERT promoter is significantly more active and rodent 
somatic tissues have more detectable telomerase activity (Horikawa et al., 2005). 
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Therefore, my finding of TERT expression in human brain cortical tissue may point to an 
important non-canonical function that has previously gone unnoticed. Furthermore, while 
brain cortical samples were used for normal comparisons to gliomas, the highest TERT 
expression was present in basal ganglia structures (caudate, nucleus accumbens, putamen 
and substantia nigra). Indicating a possible avenue of research regarding age-related 
telomere shortening and neurodegenerative diseases involving the basal ganglia such as 
Parkinson’s and Huntington’s diseases.  
 
4.3. TERT isoform expression and regulation 
The most expressed TERT isoform in all somatic tissue types was TERT_238.6. 
While Barthel et al. identified FL-TERT as the most expressed isoform in tumour 
samples, I found FL-TERT was predominant in 12/33 cancer types and TERT_238.6 was 
predominant in the remaining 21/33 cancer types. Aligned with my findings, Slusher et 
al. recently demonstrated that FL-TERT isoform percentage averaged ~22% and ranged 
from ~1% to ~54% across cancer types; whereas the ß-TERT variant averaged ~62% and 
ranged from ~40% to ~79% across cancer types. While tumour samples displayed 
increased TERT_238.6 expression, they typically experienced reduced TERT_238.6 
isoform percentage. Indicating a shift in splicing away from non-canonically functional 
TERT isoforms in the neoplastic state. Tumour samples also generally expressed six or all 
seven TERT isoforms (30/33 cancer types), whereas normal samples did so less 
frequently (10/19 tissue types). Transcriptional rate can influence alternative splicing, 
where deviation from optimal transcription alters splice site recognition and results in 
unexpected inclusions or exclusions of intronic and exonic regions (Fong et al., 2014). 
This was reinforced in my isoform expression based PCA analyses, where normal tissue 
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types with higher TERT expression had more similar plots to tumour tissues. Therefore, 
the increased TERT transcription in the neoplastic state may propagate aberrant splicing 
and the expression of isoforms that are endogenously absent in many normal tissues.  
Seeing as ß-TERT is more robustly expressed, recent efforts have uncovered 
regulatory features that govern the ß-deletion splice event. Alternative splicing is 
regulated by cis-regulatory elements, that can either be intronic or exonic splicing 
silencers/enhancers, and trans-acting factors which are RNA binding proteins (Fu & Ares, 
2014). Thus far, three ß-deletion cis-regulatory elements have been identified: block-6-
repeats (B6), direct-repeat-6 (DR6) and direct-repeat-8 (DR8). Using a TERT mini-gene 
construct containing exons 5 through 10, Wong et al. were able to identify short intronic 
repeats in intron 6 (B6 and DR6) and intron 8 (DR8) that were essential for TERT 
splicing (Wong et al., 2013). Mechanistically, they showed that B6 undergoes RNA:RNA 
pairing with sequences in intron 8 to promote the ß-deletion (removal of exons 7 and 8) 
by reducing the physical space between the splice sites at exon 6 and 9 (Wong et al., 
2014). Using varying combinations of these three cis-regulatory elements in mini-gene 
constructs and antisense oligonucleotides (ASO) to sterically hinder sites, B6 was 
considered necessary and sufficient for substantial ß-deletion, DR6 potentiated ß-deletion 
and DR8 was necessary for FL-TERT production (Wong et al., 2013). However, a 
follow-up study using two lung cancer cell lines showed that DR8-mediated splicing 
control is cell-type specific, highlighting the complexity regarding TERT expression 
regulation (Ludlow et al., 2018).  
In terms of trans-acting factors, serine/arginine proteins typically enhance exon 
inclusion, whereas heterogeneous nuclear ribonucleoproteins (hnRNP) typically enhance 
alternative splicing (Wang & Burge, 2008; Chen & Manley, 2009). Studies using ASOs 
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to target predicted SR protein binding sites on TERT have shown reduced FL-TERT and 
increased ß-TERT expression (Zhdanov et al., 2019; Wang et al., 2019). Listerman et al. 
found, using a splicing reporter minigene in breast cancer cell lines, overexpression of 
SRSF11 resulted in splicing favouring the ß-deletion over FL-TERT, whereas 
overexpression of hnRNPH2 and hnRNPL favoured FL-TERT over the ß-deletion 
(Listerman et al., 2013). Other studies using transcriptomic approaches have identified 
additional ß-deletion regulators. For example, MCPH1/BRIT1 was positively associated 
with the ß-deletion and negatively associated with FL-TERT in epithelial ovarian cancer 
(Alsiary et al., 2018). However, these and many other factors have not been 
experimentally determined to directly bind TERT pre-mRNA and are only purely 
predicted to do so. On the contrary, Ludlow et al. identified the first trans-acting factor to 
directly bind TERT pre-mRNA and modulate splicing. Using bioinformatic and 
laboratory techniques on lung cancer cells they identified and confirmed NOVA1, which 
is widely expressed in lung cancer but not in most adult tissues, directly binds to a 
conserved motif in DR8 to promote FL-TERT expression (Ludlow et al., 2018). 
Abolishing the DR8 binding motif resulted in splicing favouring ß-deleted TERT, 
decreased telomerase activity and ultimately resulted in shortened telomeres. This was the 
first instance of an experimentally confirmed trans-acting factor that regulates splicing by 
directly binding TERT pre-mRNA to modulate telomerase activity and telomere length in 
cancer. Further investigations by Sayed et al. uncovered polypyrimidine-tract binding 
protein 1 (PTBP1), a ubiquitously expressed protein in adult tissues and overexpressed in 
cancer cells that is recruited by NOVA1 to a polypyrimidine-tract binding motif 
downstream of the NOVA1 DR8 binding motif (Sayed et al., 2019). Like NOVA1, 
PTBP1 promoted FL-TERT expression, telomerase activity and telomere maintenance in 
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lung cancer cells. This provided the first insight into a splicing system that controls the ß-
deletion splice event in cancer cells.  
Translating these findings to the TCGA RNA-seq dataset, I found PTBP1 to be 
more ubiquitously overexpressed in FL-TERT expressing groups than NOVA1, which 
was only significantly increased in LUAD. Moreover, of the 33 cancer types, the top 
eight highest NOVA1 expression were from LGG, GBM, PCPG, KIRC, KIRP, SARC, 
KICH and ACC. Due to the role of NOVA1 in neuronal development (Buckanovich et 
al., 1993), it endorses the high expression in LGG, GBM and PCPG. Interestingly, LGG, 
PCPG, KIRC, KIRP, SARC, KICH and ACC were among the cancer types with a 
significant portion of TERT-negative samples. In contrast, highest PTBP1 expression 
closely matched the cancer types with the most abundant FL-TERT expression (TGCT, 
ESCA, LAML, STAD, COAD, READ, THYM, CESC) and lower percentages of TERT-
negative samples. Therefore, it is possible that PTBP1 is a ubiquitous regulator promoting 
FL-TERT irrespective of tissue type but requires another tissue specific trans-acting 
factor to direct its binding to TERT pre-mRNA. In the case of lung cancer this role is 
fulfilled by NOVA1. This underscores the conclusion that TERT expression magnitude, 
splicing patterns and regulation may be tissue and cell type specific. 
 
4.4. TERT isoform functions 
All non-FL-TERT isoforms are catalytically inactive due to splicing in the RT 
domain, frameshifts resulting in premature termination or significant insertions/deletions. 
Furthermore, the α- and ß-TERT variants result in diminished telomerase activity when 
overexpressed in-vitro (Colgin et al., 2000; Yi et al., 2000; Listerman et al., 2013). While 
the lack of isoform-specific antibodies precludes the identification of a precise inhibitory 
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mechanism, it is believed at a transcriptomic level the splicing attenuates FL-TERT 
mRNA and at a proteomic level when translated acts in a dominant-negative manner to 
sequester other enzymatic components (Liu et al., 2017b). Barthel et al. identified a 43 
gene expression signature for telomerase activity (TA) and confirmed it was significantly 
higher in tumor samples compared to normal tissue. The TA signature was also 
significantly higher in TERT-expressing cancers than non-TERT-expressing cancers and 
in tumours with TERT somatic alterations/promoter methylation than tumours harbouring 
wild-type TERT. Globally, the TA signature had a significant positive correlation with 
TERT expression in their TCGA sample subset. However, there has never been a 
transcriptomic approach used to identify the functions of TERT alternative splice 
variants. Therefore, correlating the TA gene signature to TERT isoform percentage I 
found significant positive correlations to FL-TERT (9/33 cancer types) and significant 
negative correlations to TERT_238.6 (14/33 cancer types). The overall significant 
relationship between increased TERT_238.6 isoform percentage and decreased TA 
signature score, indicates that ß-deletion splicing possibly plays a role in regulating TA 
and confirms previous findings of ß-TERT-mediated hindrance on telomerase-mediated 
telomere maintenance (Listerman et al., 2013; Akincilar et al., 2015). However, many 
cancer types did not have significant correlations, pointing towards a potential caveat 
against the signature score’s utility to accurately measure telomerase activity and any 
functional inferences made on TERT isoform functions across cancer types. 
Another measure of TA is telomere length (TL), as the final canonical detriment 
of TERT expression is telomere re-lengthening. However, the relationship between TERT 
expression and telomere re-lengthening is controversial. Studies evaluating endogenous 
TERT expression have found either no correlation, positive correlations or negative 
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correlations with TL (Hu et al., 2010; Wang et al., 2011; Butler et al., 2012; Lötsch et al., 
2013; Palma et al., 2013; Svahn et al., 2018). Alternatively, studies experimentally 
altering splicing patterns away from FL-TERT have consistently observed relative 
telomere shortening (Colgin et al., 2000; Yi et al., 2000; Listerman et al., 2013) and 
studies overexpressing FL-TERT have consistently observed telomere lengthening and 
maintenance (Bodnar et al., 1998; Vaziri & Benchimol, 1998; Counter et al., 1998). More 
recently, Rowland et al., used single-molecule RNA FISH on various cancer cells lines 
and observed no significant correlation between TERT expression and TL (Rowland et 
al., 2019). Similarly, I found no consistent relationship between TERT isoform 
expression and TL ratio. Three cancer types (SARC, TGCT, THYM) presented 
significant correlations between total TERT expression and TL ratio. From these, TGCT 
and THYM had positive correlations and were also the top two in total TERT expression. 
Conversely, in SARC, I observed a significant negative correlation between TERT or FL-
TERT expression and TL ratio. This potentially reflects the telomerase-mediated TMM 
decision fate in cancer types enriched for ALT-mediated TMM. Interestingly, a recent 
transcriptomic Pan-Cancer analysis of TMM-pathway genes, found enhanced expression 
of TMM-related genes in TGCT, THYM, and SARC (Sung et al., 2020). Moreover 
TGCT, THYM, and SARC were cancer types identified with a greater proportion of 
telomere elongated samples (Sung et al., 2020). Therefore, the penetrance of TERT 
expression on telomere length is cancer type specific. Presenting positively in cancer 
types where the magnitude of overexpression offsets intermediate regulatory steps but 
negatively in cancer types where a prevalent ALT phenotype is juxtaposed.  
From a prognostic perspective, TERT promoter mutations (Ramlee et al., 2016) 
and total TERT overexpression (Wang et al., 2018a) have been associated with poor 
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survival or progression in various cancer types. Expectedly, I found poorer prognoses to 
be associated with increased total- or FL-TERT in six cancer types (COAD, PRAD, 
SARC, MESO, KIRP, THCA). However, clinical outcomes were most significantly 
impacted by tumour stage or subtype. Interestingly, I found a few cancer types to have 
improved prognosis with increased total TERT expression. Some had more direct 
plausible explanations such as improved OS in thymic tumours with increased immune 
cell infiltration (Radovich et al., 2018) or improved OS in atypical HNSC tumours that 
are characterized by Human Papillomavirus (HPV) positive status (TCGA Network, 
2015a). HPV(+) tumours have improved survival (Tahtali et al., 2013; TCGA Network, 
2015a; Wookey et al., 2019) and the early (E) HPV viral genes E6 and E7 do activate 
TERT gene expression (Katzenellenbogen, 2017), explaining the perplexing outcome of 
improved survival with increased TERT expression. Conversely, the prognostic potential 
of specific TERT isoforms remains unclear. Unfortunately, cancer types with isoform-
specific effects on prognoses such as SKCM with poorer OS by αßγ-TERT, MESO with 
poorer OS and PFI by ß-TERT, KIRC with poorer PFI by αßγ-TERT, OV with improved 
PFI by γ-TERT or THCA with poorer PFI by αßγ-TERT, all suffered from small sample 
sizes in their isoform expressing groups. While the expression of these TERT isoforms 
may directly impact prognoses through TMM decision fate or indirectly through non-
canonical functions, it is also plausible they are a consequence of broader splicing 
dysregulation entrenched in the hallmarks of increased cancer aggression (Oltean & 
Bates, 2014; Bonnal et al., 2020). Moreover, the correlation between TMM pathway 
activation and tumour progression is dependent on both TL and cancer type (Sung et al., 
2020). Overall, this suggests the magnitude and direction of effect that TERT expression 
patterns have on telomere length and tumour progression is tumour-type specific. 
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Highlighting the importance of future investigations into TERT isoform function and 
clinical utility in specific cancer types using large cohorts. 
 
4.5. TERT isoform expression in cancer cell lines  
To guide future cancer specific investigations into TERT isoforms, I clustered 
cancer cell lines with their related primary tumours to identify those most representative 
of their associated primary tumour’s TERT transcriptome. The CCLE dataset has 
previously shown a significant correlation (r = 0.84, p < 0.05) between COSMIC 
(Catalogue of Somatic Mutations in Cancer) mutational signatures to tissue-specific 
TCGA tumours (Ghandi et al., 2019). Similarly, there was correlative agreeability 
between transcriptional profiles (n = 5000 most variable genes) between tissue specific 
CCLE and Toil recomputed TCGA and GTEx datasets (Ghandi et al., 2019). These 
findings reinforced the compatibility of the TCGA, GTEx, and CCLE datasets.  
While many cell lines lacked TERT promoter status data, by annotating those with 
their TERT promoter status (Ghandi et al., 2019), we can probe future TERT promoter 
alteration studies. For example, recent findings have shown MESO tumours harbouring 
TERT promoter mutations are associated with poor survival, increased promoter activity, 
TERT expression, but no change in telomerase activity or telomere length (Quetel et al., 
2020; Pirker et al., 2020). Therefore, by using suitable TERT promoter mutated 
(NCHI2052) and wild-type (ISTMES2) pleural cell lines, researchers can investigate how 
TERT promoter mutations and consequentially increased TERT expression may function 
through non-canonical pathways to generate poorer prognoses in mesotheliomas.  
While my clustering was based solely upon TERT isoform expression patterns, 
research groups have taken on the massive undertaking of associating CCLE cell lines 
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with TCGA tumours using the whole “omic” data. Of note, Yu et al. used the 
transcriptome (expression of the 5000 most variable genes) to match the most 
representative CCLE cell line to each of 22 TCGA primary tumour types, with the 
exception of SKCM which they used metastatic tumours (Yu et al., 2019). Interestingly, 
they observed eight tumour types with higher transcriptomic correlations with cell lines 
originating from another tumour type and the negative influence of immune cell 
infiltration on tumour purity and subsequent cell line correlations. All things considered, 
they highlight the importance of cell line selection and to assist researchers developed a 
comprehensive panel (TCGA-110-CL) of five cell lines with the highest correlation for 
each of 22 tumour types. Intriguingly, 8/21 tumour types (excluding SKCM because my 
study used primary tumours as opposed to metastatic) had a cell line from the TCGA-
110-CL that my study also recommended based solely on TERT isoform expression 
patterns. Specifically, BLCA and cell lines RT4 and CAL29 were recommended by 
TCGA-110-CL and my clustering analysis, CHOL (cell lines SNU869 and HUCCT1), 
LAML (cell line OCIAML5), LGG (cell line TM31), LIHC (cell line HEPG2), MESO 
(cell line ISTMES2), OV (cell line COV362) and PAAD (cell line CAPAN1) had both 
recommendations. Thus, further reinforcing the use of the outlined cancer cell lines for 
TERT isoform research in these eight tumour types.  
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Chapter 5 – Conclusion 
5.1. Summary and conclusion 
 In this thesis, my focus was on telomerase-based telomere maintenance, 
specifically the expression, function, regulation and consequences of TERT. I evaluated 
these components in both the normal and neoplastic states for a variety of tissue types.  
 This journey began by investigating TERT isoform expression using the available 
online tools (outlined in Section 2.1.2) developed for TCGA and GTEx “omic” analytics. 
While providing a broad overview, there were many inconsistencies and cumulatively 
they fell short of the breadth of exploration I initially set out for. Fortunately, the Toil 
recomputed dataset with TERT isoform expression in both TCGA and GTEx samples was 
publicly available. I confirmed the status of TERT overexpression in cancer cells, 
discussed TMM decision fate and identified normal cell types with unexpected TERT 
expression levels, particularly in brain tissue. This indicates TERT regulation at the 
epigenetic and/or (pre)transcriptional levels that is occurring in a tissue-specific manner. 
This tissue-specificity suggests that TERT overexpression during tumorigenesis is not a 
conserved mechanism, but rather a myriad of possible alterations that seek to achieve the 
same goal of increased TERT expression. At an isoform level I also found, consistent 
with previous findings, tissue and cell-specific heterogeneity. Notably, cancer types such 
as PCPG that expressed the lowest mean TERT, was predominantly TERT-negative and 
enriched to express solely TERT_238.6. However, UVM which had the second lowest 
mean TERT expression was enriched to express solely FL-TERT. While transcriptional 
rate has been proposed to impact RNA splicing, clearly other mechanisms are also at 
play. Moreover, the developmentally related expression in non-seminoma testicular 
tumours is an example of cell and tissue subtype dependent TERT expression patterning. 
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Overall, the prevalence of ß-deletion splicing manifested through a novel isoform, 
TERT_238.6. Nonetheless, I proposed the ß-deletion splice regulator NOVA1 is specific 
to lung cancer and likely acts in concert with more ubiquitous regulators such as PTBP1. 
Through tumour subtype analyses I reinforced the theory of RB1-mediated ALT 
activation, as well as proposed mechanisms by which specific cancer subtypes alter 
TERT expression. Finally, by investigating functional and clinical outcomes of TERT 
isoforms I brought to light the cancer specific nature and impact of TMMs. All things 
considered, I have provided a comprehensive Pan-Cancer characterization of the TERT 
transcriptome, highlighted the massive heterogeneity in TERT isoform expression and 
regulation, reinforced the necessity of cancer-type specific investigations, and provided 
some avenues of future focus.  
In conclusion, my efforts have contributed towards identifying the differences in 
TERT isoform expression patterns, regulation and contribution to TMM decision fate. In 
addition, I emphasize the importance of tissue-type specific TERT research and detail 
specific cancer cell lines for each tumour type as a starting place for such investigations. 
To my knowledge, this is the first normal and neoplastic characterization of the TERT 
transcriptome across tissue types.   
 
5.2. Methodological limitations  
5.2.1. RNA-sequencing datasets  
One bottleneck of this study, specifically for a Pan-Cancer perspective, is the 
requirement of large multi-tissue datasets to minimize batch-effects from various RNA-
seq protocols. Therefore, the ideal primary candidate was The Cancer Genome Atlas 
(TCGA) project (Weinstein et al., 2013). This project, a collaboration between the 
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National Cancer Institute and the National Human Genome Research Institute, analyzed 
over 11,000 tumours from 33 distinct cancer types. This robust dataset includes genomic 
(gene copy number, somatic mutations), transcriptomic (mRNA and miRNA expression), 
proteomic (protein expression), epigenetic (DNA methylation) and clinical phenotypic 
information (Ding et al., 2018; Hoadley et al., 2018; Sanchez-Vega et al., 2018). Of 
interest to this study is the TCGA mRNA expression data that was generated from RNA-
seq. Briefly, TCGA originally released “legacy” data which was aligned to the human 
Genome Reference Consortium build 37 (GRCh37, also known as hg19) (Church et al., 
2011) and quantified for isoform-level expression. When the GRCh38 (hg38) build was 
released (Schneider et al., 2017), TCGA responded by creating the Genomic Data 
Commons (GDC) to harmonize the TCGA data using up-to-date pipeline tools and align 
reads against the updated reference genome (Gao et al., 2019). Unfortunately, expression 
quantification was conducted at a gene-level. 
To determine the cancer-specific changes in TERT ASV expression, a normal 
tissue RNA-seq dataset was required (Kilpinen et al., 2011). The Genotype-Tissue 
Expression (GTEx) project, which began with a two-and-a-half-year pilot phase to 
determine the feasibility of generating high-quality data from post-mortem donors, has 
grown to over 11,000 samples from 53 tissue types (GTEx Consortium, 2013; Battle et 
al., 2017). The GTEx project continues to release updated versions of RNA-seq analyses; 
the current V8 release has both gene- and isoform-level expression quantification. 
Only TCGA legacy data had comparable isoform-level expression quantification 
to GTEx data; necessary for an evaluation of TERT isoforms. However, the paramount 
differences between TCGA legacy and GTEx RNA-seq methodology were unavoidable. 
Namely, the alignment tools (MapSplice vs. STAR), reference genome (GRCh37 vs. 
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GRCh38) and transcriptome annotation (UCSC knownGene vs. Gencode v26). 
Serendipitously, recent studies have tackled the massive computational undertaking of 
recomputing raw reads from both TCGA and GTEx datasets under a unified pipeline for 
permissive comparisons of normal and neoplastic tissues (Vivian et al., 2017; Wang et 
al., 2018b). While Wang et al. also removed study dependent batch corrections, their 
pipeline only quantified gene-level expression. Although prior to this in 2017, Vivian et 
al. created the Toil pipeline to unify and compute both gene- and isoform-level RNA-seq 
expression values for TCGA and GTEx datasets. They did so, using the most recent 
reference genome GRCh38 and the Gencode v23 transcript annotation. Detailed 
methodology for TOIL recomputed RNA-seq data can be found in Appendix A. However, 
the caveat that Toil recomputed data lacks batch correction must be kept in mind (Wang 
et al., 2018b). Nevertheless, the Toil recomputed data was unmatched among all publicly 
available datasets that would permit accurate comparisons between normal and neoplastic 
tissues at an isoform-level.  
A plethora of online tools have been developed to explore the omics of large 
cancer and normal datasets. The GDC data portal and cBioPortal provide easy to navigate 
platforms to broadly characterize and assess the phenotypic consequences of cancer 
datasets at a gene-level (Cerami et al., 2012). Reviewed by Zhang et al. are various tools 
to perform global, targeted or auxiliary analyses on TCGA omics data (Zhang et al., 
2019). Specifically providing isoform-level data interpretations were TCGASpliceSeq 
(Ryan et al., 2016), ISOexpresso (Yang et al., 2016) and TSVdb (Sun et al., 2018). 
However, these tools fell short as they utilized TCGA legacy data. GEPIA2 (Tang et al., 
2019) and UCSC Xena (Goldman et al., 2020) both housed the Toil recomputed TCGA 
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and GTEx datasets. UCSC Xena was superior as the TCGA samples could be delineated 
by sample type (i.e. primary versus metastatic tumours). 
While the TCGA project also excised and sequenced adjacent normal tissue 
samples from some cancer patients (Huang et al., 2016), these “normal” tissue samples 
may be affected by neighbouring tumour cells. Common tumorigenic changes such as 
altered intercellular signaling and inflammation, which may be compounded with effects 
from improved vascularization in the tumour region, can certainly impact the 
transcriptomic state of neighbouring “normal” cells (Zhao et al., 2013; Jones et al., 2015; 
Casbas-Hernandez et al., 2015; Suntsova et al., 2019). Moreover, the TCGA normal 
samples had significantly different TERT isoform expressions/percentages than matched 
GTEx normal tissue samples (Appendix B.1). Therefore, the decision was made to 
exclude TCGA normal samples and solely compare TCGA tumour samples to GTEx 
normal samples. 
 
5.2.2. RNA-sequencing analysis 
One of the most prominent limitations of this analysis is the failure to integrate the 
concepts of compositional data analysis (CoDA). Sequencing data, by nature is 
compositional (Fernandes et al., 2014). Since only a fixed number of sequences are 
generated (sequencing depth), the abundance of any component is relative to another 
component (i.e. increased abundance of one component will decrease the observed 
abundance of other components). Due to this, the data exists in a simplex space (closed 
and dependent), rather than a Euclidean space (open and independent). Thus, applying 
conventional statistical techniques to compositional data can be problematic. Some 
common issues that arise are scale invariance, where changing the magnitude of data 
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proportionally will be interpreted differently in a Euclidean physical space, or sub-
compositional coherence, where analytic outcomes are different when components are 
excluded (van den Boohgaart et al., 2013). To appropriately adjust compositional data for 
effective comparisons, two main techniques have emerged.  
Most commonly used is a normalization-dependent technique. In this method, the 
reads are normalized to the read depth and the transcript length. Raw counts for a gene 
between samples are not comparable because the sequnecing depth (total number of 
mapped reads) may vary. For example, samples sequenced at twice the depth could have 
twice the number of mapped reads, but this would not be indicative of greater expression. 
Raw counts for a genes within a sample are also not comparable because longer 
transcripts would generate more “sequenceable” fragments and consequently result in 
more mapped reads. Therefore, normalizing to fragments Per Kilobase of transcript per 
Million fragments mapped (FPKM) or transcripts per million (TPM) are commonly used. 
In FPKM, counts are normalized by dividing the number of mapped reads by the scaling 
factor (total number of reads divided by million) multiplied by the transcript length. In 
contrast, TPM normalizes for gene length before sequencing depth. Read counts are first 
divided by gene length to generate reads per kilobase (RPK). The sum of all RPK values 
are divided by one million to generate a per-million scaling factor. Each RPK value is 
divided by this scaling factor to generate TPM values. This difference in the order of 
normalization operations means the sum of all TPM values is the same in every sample. 
This allows for an easier comparison of the proportion of mapped reads to a specific 
transcript of interest between samples. However, the direct comparison of FPKM/TPM 
values is only relevant when the assumptions are made that sample groups have equal 
amounts and distributions of total RNA (Zhao et al., 2020). Moreover, differences in 
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sample preparation and RNA compartmentalization across tissues can inflate or deflate 
relative abundances (Zhao et al., 2020).  
Another form of normalization, which attempts to retrieve absolute abundances 
does so by scaling the sample’s read library by a reference (Dillies et al., 2013). For 
example, the reference that the DESeq program (Anders & Huber, 2010) uses, is the 
median of the ratios for each gene in a sample to the geometric mean of each gene for all 
samples. Alternatively, the edgeR program (Robinson et al., 2010) uses the weighted 
mean of log ratios between a sample and an explicitly chosen reference, as the overall 
scaling reference. However, these methods don’t explicitly take into account the 
compositional nature of RNA-seq data and also require the assumption that most 
transcripts have the same abundance across samples. An often-cited failure to this 
assumption is high c-Myc cells, which upregulate 90% of all transcripts (Lovén et al., 
2012). Since c-Myc is overexpressed in the majority of cancers, this means comparisons 
to normal tissues may be skewed (Miller et al., 2013). One possible remedy for this 
computational problem is the use of spike-in controls (Jiang et al., 2011). These controls 
are added into samples at the same abundance before the sequencing step, such that their 
read counts across samples are uniform. However, in real-life the experimental 
constraints are not only at the sequencing step, but the generation of sample material or 
evens the cells capacity to synthesize nucleotides are also variable and inherently 
compositional (Quinn et al., 2018).  
The second technique is CoDA (Aitchison, 1986) and involve various 
mechanisms to transform the data. This technique, while applicable to relative (TPM) or 
absolute (raw counts) data, do not attempt to retrieve the true absolute counts from 
sequencing data. Rather, by taking the relative log-ratio transformations of the 
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components to a reference, the data can be treated in a Euclidean space and permits 
conventional statistical techniques. Similar to using spike-in controls, the additive log-
ratio (ALR) technique transforms data uses a specific chosen reference to transform data. 
Although the disadvantage becomes choosing the appropriate reference and making sense 
of the data in relation to that reference. Instead of a specific reference, the centered log-
ratio (CLR) technique uses the geometric mean of a sample’s read library as the 
reference, prior to log transformation. Other methods include but are not limited to the 
inter-quartile log-ratio transformation (IQLR), which is similar to CLR but instead takes 
only the geometric mean of transcripts within the interquartile range of variance. 
Regardless of choice, each type of log-ratio transformation must be interpreted to the 
chosen reference. Using a program such as ALDEx2 is best suited for CoDA (Fernandes 
et al., 2014).  
Finally, with respect to the cell line comparisons, the transcriptome annotation 
used for the TCGA and CCLE datasets were different. There were seven TERT 
transcripts for TCGA and eight transcripts for CCLE. I adjusted for this by attributing the 
reads for TERT_820.5 to TERT_104.2 (ß-TERT) due to their structural similarity. 
However, this is not to say the distribution of RNA-seq reads would be congruent if the 
CCLE dataset was recomputed using a more recent TERT transcript annotation with 
seven transcripts. 
 
5.2.3. Statistical correction for multiple comparisons 
 Simply put, using an alpha value of p = 0.05 for significance would mean 
hypothetically conducting 100 comparisons would result in 5 significant observations by 
chance. This increased probability of false positives (type I error) must be accounted for.  
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One method is to adjust the threshold for significance, used in this thesis, is the 
Bonferroni correction. Using this method, the original alpha is multiplied by the number 
of tests being conducted. For example, in my tumour-normal comparisons there were 19 
pairs for 8 expression-based variables (TERT isoforms + total TERT) and 7 percentage 
based variables; in total 19*8 + 19*7 = 285 comparisons. That would make the adjusted 
p-value at ~ 0.000175 (0.05/285). While effective, this method if conservative and can 
increase the probability of false negatives (type II error).  
 An alternative approach is the Benjamini and Hochberg method (Benjamini & 
Hochberg, 1995). Rather than adjusting for false positives, this method controls the rate 
of false discovery (FDR) by determining the expected number of false positives among 
all positives, rather than the total number of tests. Using this method, all P-values are 
ranked in an ascending order and multiplied by the quotient of the number of total tests 
divided by their ranked position. This less conservative method may be a better balance 
between controlling for false positives but minimizing the occurrence of false negatives.  
 
5.2.4. TERT transcript annotation 
Notably, the TERT isoforms TERT_238.6, TERT_656.1 and TERT_877.1 have 
either been briefly mentioned or are unmentioned in the literature encompassing this field 
of research. TERT_238.6 has been cited twice but using UCSC Genome Browser 
nomenclature that was assembled using GRCh37, as opposed to the current GRCh38. In 
this archived UCSC build, TERT_238.6 is called uc003jbz.1. Firstly, Dahlin et al. 
investigated the relationship between glioma risk variants and DNA methylation (Dahlin 
et al., 2016). In doing so, they found an association between a TERT expression 
increasing risk variant (rs2736100) and lower levels of methylation at a specific CpG 
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probe site (cg238279091) localized to the first exon of the uc003jbz.1 TERT isoform. 
More recently, Slusher et al. reviewed the alternative splicing of TERT and using the 
online platform TSVdb (Sun et al., 2018) showed the most common splice event in the 
TCGA dataset was the ß-deletion. The TSVdb platform houses TCGA legacy data which 
was also assembled against GRCh37 and annotates TERT_238.6 as uc003jbz.1. In their 
review, the TERT_238.6/uc003jbz.1 variant was indicated to undergo nonsense-mediated 
decay (NMD). While the ß-TERT variant generates a prematurely terminated transcript 
that largely undergoes NMD, it is also translated into a truncated protein using the same 
open-reading frame (ORF) at FL-TERT (Listerman et al., 2013). However, TERT_238.6 
has additional deletions of exons 1 and 2 and a 386bp insertion of intron 3 prior to exon 3. 
Interestingly, this insertional location has been previously observed. Using 5’ and 3’ end 
primers, Hrdličková et al. was able to identify 22 distinct TERT isoforms, three of which 
had insertions prior to exon 3 (Hrdlicková et al., 2012). Specifically, a 349bp insertion 
resulting in a premature stop codon within the insertion, a 167bp insertion that maintained 
the canonical ORF and an insertion of unknown size that also contained a premature stop 
codon within the insertional element. Although, none of these splicing events matched the 
386bp insertion defined by TERT_238.6. Using NCBI ORFFinder (Wheeler et al., 2003), 
the longest ORF for TERT_238.6 was ~250 amino acids (in comparison FL-TERT spans 
1132 amino acids) and was located in the middle of the transcript. Thus, TERT_238.6, if 
transcribed most likely does not get translated and undergoes NMD.  
With respect to TERT_656.1 and TERT_877.1, which span about two exons each, 
there were no citations found indicating their presence in vitro. Among the 22 splice 
variants found by Hrdličková et al. there were isoforms harbouring large deletions such as 
∆2-13, which is a deletion of exons 2 through 13 (Hrdlicková et al., 2012). Moreover, 
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Sayed et al. used targeted long-read length RNA sequencing to identify TERT isoforms 
present in HeLa cells (Sayed et al., 2019). The five most abundant TERT isoforms 
consisted of FL-TERT, ß-TERT, γ-TERT, ∆5-15 (deletions of exons 5 through 15) and 
∆4-15 (deletions of exons 4 through 15). Therefore, there are observations of short TERT 
transcripts. Though sequencing technology has provided quantification and identification 
of novel TERT isoforms there are potential avenues for misinterpretation. Particularly, 
poly-A-selection results in 3’ bias of selected RNA transcripts and the high 5’ guanine-
cytosine content in exons 1 and 2 of TERT hinders accurate detection (Udvardi et al., 
2008). Moreover, the scarcity of TERT expression requires large sequencing depth 
(Raithel et al., 2016). For these reasons, Barthel et al. opted to focus on sequencing and 
analysis of exons 6-9, thus limiting coverage solely to the ß-deletion. Therefore, 
conclusions regarding TERT_238.6 may be taken simply as the ß-deletion as done by 
Slusher et al. but could also represent a novel distinct isoform. Similarly, conclusions 
regarding TERT_656.1 and TERT_877.1 may be RNA-sequencing artifacts but could 
also represent novel short isoforms that have been previously observed. Moving forward, 
these reservations must be kept in mind until either the Toil RNA-seq dataset is re-
analyzed using an updated annotation of TERT isoforms that accurately reflects those 
observed in vitro, or RNA-seq biases are mitigated.  
Newer technologies can be employed to overcome this technical hurdle. For 
example, Pacific Biosciences and Oxford Nanopore offer long read length RT-PCR 
sequencing which can remove isoform ambiguity (Stark et al., 2019). There also exists 
targeted RNA-sequencing via RNA enrichment which can be applied to accurately 
identify and quantify low abundance transcripts like TERT (Minervini et al., 2016; Stark 
et al., 2019). Using long read length sequencing, as done by Sayed et al., removes 
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isoform ambiguity but is limited by primer locations (Sayed et al., 2019). In their study, 
primers were positioned on exons 1 or 2 and exons 16, meaning any TERT isoforms with 
deletions of these exons would not be identified. Therefore, a combination of these 
technologies may be required. Direct sequencing, without prior cDNA library 
preparation, removes PCR-based biases but is restricted because PCR-based amplification 
permitted the use of smaller amounts of initial RNA (Stark et al., 2019). For lowly 
expressed genes like TERT, enrichment of RNA by targeting both exonic and intronic 
regions followed by direct long-read RNA sequencing from the 3’ poly-A-tail to 5’ cap 
will allow for the most accurate identification and quantification of TERT isoforms. 
 
5.2.5. Telomere length measurements  
Consistency in telomere length measurement techniques, discussed by Pepper et 
al., is necessary to understand the impact of telomere maintenance across tissue types 
(Pepper et al., 2020). Since cancer can be thought of as an inflammatory disorder, many 
studies have used normal peripheral leukocyte telomere length directly or indirectly as 
markers of prognosis. Moreover, an immune hypothesis has emerged suggesting a 
suppressed immune response leads to fewer cell divisions and thus longer leukocyte 
telomeres, suggesting tumour progression (Cleal et al., 2018). On the flip side, a chronic 
pro-inflammatory tumour microenvironment may result in continued immune cell 
activation, division and telomere erosion (Maimela et al., 2019). Some studies have 
observed a bi-modal association where both extremely short and long telomere lengths 
are indicative for poor prognoses, possibly alluding to overactive or suppressed immune 
responses, respectively (Skinner et al., 2012; Wang et al., 2014; Du et al., 2015).  Pepper 
et al. argues that mean telomere length estimates using bystander cells seems 
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counterproductive as leukocytes originating from heterogenous origins (i.e. many 
different haematopoietic stem cells) will have undergone varying number of cell divisions 
and consequently have varying levels of telomere shortening (Pepper et al., 2020), thus 
making it difficult to draw conclusions on its prognostic value. Ideally, telomere length 
measurements pre and post-tumorigenesis in conjunction with telomerase enzymatic 
activity levels would provide a clearer picture of the role telomere maintenance has on 
cancer prognoses. 
 
5.3. Future perspectives  
My study focused primarily on the mRNA transcriptome to characterize TMMs, 
investigate TERT isoform functions and prognostic outcomes and perform clustering. 
However, TERT is regulated by multiple modalities (Jie et al., 2019) that should be 
integrated to holistically characterize the TERT “omic” picture. Pre-transcriptionally, 
there is epigenetic crosstalk whereby TERT influences the epigenetic state but is also 
regulated by promoter methylation and histone acetylation. For example, in the TCGA 
dataset, TERT expression is positively correlated with DNA Methyltransferase 3B 
(DNMT3B), resulting in methylation-based silencing of phosphatase and tensin homolog 
(PTEN) (Yuan & Xu, 2019). Since PTEN inhibits PI3K/AKT signaling, the consequential 
overactivation results in a pro-proliferative anti-apoptotic state (Yuan & Xu, 2019). While 
TERT promoter methylation and genomic alterations can increase expression (Barthel et 
al., 2017), there is a plethora of transcription factors, that if aberrantly expressed, 
contribute to dysregulating TERT expression (Ramlee et al., 2016). Post-
transcriptionally, in addition to alternative splicing, several micro-RNAs and long non-
coding RNAs regulate TERT expression (Jie et al., 2019). For example, recently mir-615-
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3p was shown to repress TERT expression by targeting the 3’ UTR in cancer cells and 
overexpression suppressed tumorigenesis in-vitro and in-vivo in mouse models (Yan et 
al., 2018).  Finally, post-transcriptional modifications, namely phosphorylation and 
ubiquitination, can affect TERT steady state levels, localization and enzymatic activity 
(Jie et al., 2019). Unfortunately, the lack of isoform-specific antibodies restricts 
proteomic investigations into TERT isoform translation and possible subsequent 
modifications. Generating a complete network of factors regulating TERT expression, 
regulation and modification is daunting if not currently improbable. However, the 
heterogeneity of TERT expression and downstream telomeric and non-telomeric effects 
alludes to use of several regulatory mechanisms across all “omic” levels. Therefore, a 
truly comprehensive characterization should integrate as many of these regulatory steps 
as possible. In doing so, we may finally understand how normal tissues repress 
telomerase activity and the various mechanisms by which neoplastic tissues 
reactivate/maintain telomerase activity via TERT dysregulation.   
 Once we understand how telomerase activity is promoted, we can develop more 
effective therapies. In a recent review, Trybek et al. outlines the various telomerase-
targeted therapies that utilize various strategies to inhibit telomerase activity (Trybek et 
al., 2020). Notably Imetelstat, an ASO, competitively antagonizes TERC and its 
recruitment to telomeres (Röth et al., 2010). While tested in various cancer types, its high 
toxicity has limited its use a stand-alone therapy but has shown promise for haematologic 
myeloid malignancies (Trybek et al., 2020). One of the major drawbacks of anti-
telomerase therapies are the long lag time between treatment initiation and adequate 
telomere attrition for cancer cell death. During this period, the cancer progresses, and 
treatment related toxicities accrue. Mitigating this risk may involve the use telomerase 
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inhibitors in conjunction with conventional first-line therapies (Slusher et al., 2020). One 
possible avenue is the use of ASOs to artificially alter TERT splicing patterns in a 
personalized manner depending on the tissue type, tumour subtype and severity of 
disease. Moreover, as Slusher et al. indicates, we have already witnessed the success of 
this technology in the treatment of spinal muscular atrophy (SMA). SMA patients with 
defective SMN1 (survival motor neuron protein 1) are treated with Nusinersen, an ASO 
which reworks SMN2 SMN1 (survival motor neuron protein) splicing to compensate for 
SMN1 deficiency (Ottesen, 2017). Albeit, SMA researchers are armed with in-depth 
understanding of cis-regulatory elements and trans-acting factors that govern SMN1/2 
splicing (Singh & Singh, 2018). Therefore, following a step-wise process of (1) 
characterizing isoform expression differences and their phenotypic manifestations; will 
then allow for (2) comparisons between cell types with dissimilar TERT transcriptomes to 
evaluate the regulatory mechanisms that produce such differences; then (3) leverage these 
findings to target regulatory mechanisms in representative cell lines and exploit beneficial 
TERT splicing; which would ultimately (4) lead to possible cancer therapeutics.  
 
5.4. Closing remarks  
 Sequencing costs have improved drastically over the last two decades, faster than 
predicted by Moore’s Law, allowing for large scale projects such as TCGA, GTEx and 
CCLE. With the plethora of “omic” data obtained researchers have been empowered, 
more than ever, to elucidate the drivers of neoplastic transformation and progression, and 
provide clinically actionable guidance on diagnoses, prognoses and therapeutic 
interventions. Herein, I scratch the surface on characterizing the TERT transcriptome and 
outline possible research avenues in various normal and neoplastic tissue types. The next 
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challenge will be integrating the multiple facets of TERT regulation and removing the 
ambiguity of isoform-level RNA-sequencing while sustaining the large-scale feasibility 
necessary to uncover cell-type specific nuances and novel cancer therapies.  
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Appendix 
Appendix A: RNA Sequencing Methods 
 
A.1.  TCGA legacy 
TCGA RNA samples were processed using poly-A selection and sequenced using 
either Illumina Genome Analyzer or HiSeq to generate primarily 100 or 101 base-pair (bp) 
reads (ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020). 
Originally using MapSplice (Wang et al., 2010a), the RNA-seq data was aligned to the 
human Genome Reference Consortium build 37 (GRCh37, also known as hg19) (Church 
et al., 2011), and annotated using the UCSC “knownGene” transcriptome. This data, 
referred to as “legacy” data (Gao et al., 2019) utilized RSEM (Li & Dewey, 2011) for 
expression quantification and provided both normalized gene-level and isoform-level read 
count estimates and scaled estimates that when multiplied by one million are equivalent to 
transcripts per million values. 
 
A.2.  TCGA harmonized  
The Genomic Data Commons (GDC) was created to “harmonize” the TCGA data 
using up-to-date pipeline tools and align reads against the updated reference genome (Gao 
et al., 2019). The workflow involved reverting aligned legacy files into unprocessed read 
data, which was subsequently aligned to the GRCh38 and annotated using Gencode v22 
(Frankish et al., 2019) transcriptome. Expression quantification using htseq-counts only 
provided gene-level fragments per kilobase of transcript per million mapped reads values. 
 
A.3.  GTEx  
GTEx sample libraries were prepared using the Illumina TruSeq protocol that 
utilized poly-A selection for mRNA enrichment. Subsequent sequencing on HiSeq 2000 or 
HiSeq 2500 generated 76 bp reads at a median depth of 82 million reads per sample (GTEx 
Consortium, 2013). The current V8 release in 2019 used STAR (Dobin et al., 2013) to align 
reads to GRCh38 (Schneider et al., 2017), annotated using Gencode v26 (Frankish et al., 
2019) and performed gene-level quantification using RNA-SeQC (DeLuca et al., 2012), as 
well as isoform-level quantification using RSEM (Li & Dewey, 2011) to generate read 
counts and TPM values. 
 
A.4. Toil Recompute 
 CutAdapt was used for adapter trimming, STAR (Dobin et al., 2013) was used for 
alignment, and RSEM (Li & Dewey, 2011) and Kallisto (Bray et al., 2016) were used as 
quantifiers. Reference genome was GRCh38 (Schneider et al., 2017) and transcript 
annotation used was Gencode v23 (Frankish et al., 2019). Generated TPM expression and 
isoform percentage values.  
 
A.5.  CCLE 
 CCLE samples were prepared using Illumina Truseq RNA preparation protocol, 
poly-A-selected for mRNA and sequenced by either Illumina HiSeq200 or HiSeq2500 for 
no less than 100 million, 101bp long reads per sample. Reads were aligned by STAR 
(Dobin et al., 2013) using GRCh37 reference genome (Church et al., 2011) and Gencode 
v19 (Frankish et al., 2019) for gene/transcript annotations. Isoform-level TPM values 
were quantified using RSEM (Li & Dewey, 2011). 
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Appendix B: Sample Data Management and Filtering 
 
B.1.  Comparison of TERT isoform expression and percentage between matched 
tissue types for TCGA normal samples and GTEx samples 
 
 
Figure B.1. There were 11 tissue types with both TCGA normal, TCGA tumour and GTEx 
normal samples. To determine whether to use TCGA normal or pool TCGA normal and 
GTEx normal samples, TERT isoform expression and percentage was compared using 
Welch’s t-test. Tissue types are labels as column headers with TCGA:GTEx sample number 
comparison. Pancreatic, brain and esophageal tissue types were excluded because TCGA 
samples constituted less than 2% of total pooled samples within each tissue type. 
“ISOPCT” denotes isoform percentage which was log2(isoform percentage, 1) transformed. 
“EXP” denotes expression which was log2(TPM, 0.001) transformed. Red highlight 
indicates a significant difference (p < 0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stomach (36:174) Prostate (52:100) Lung (109:228) Liver (50:110) Kidney (129:28) Colon (41:308) Breast (113:179) Bladder (19:9)
ISOPCT TERT_877.1 ISOPCT TERT_877.1 ISOPCT TERT_877.1 ISOPCT TERT_877.1 ISOPCT TERT_877.1 ISOPCT TERT_877.1 ISOPCT TERT_877.1 ISOPCT TERT_877.1
p = 0.6526 (t = 0.4530) p = 0.3173 (t = -1.005) p = 0.1597 (t = -1.410) p = NaN (t = NaN) p = NaN (t = NaN) p = 0.9650 (t = -0.04404) p = 0.3173 (t = -1.003) p = NaN (t = NaN)
ISOPCT FL-TERT ISOPCT FL-TERT ISOPCT FL-TERT ISOPCT FL-TERT ISOPCT FL-TERT ISOPCT FL-TERT ISOPCT FL-TERT ISOPCT FL-TERT
p = 0.6611 (t = 0.4411) p = 0.5761 (t = 0.5610) p = 0.3085 (t = 1.021) p = 0.08054 (t = 1.784) p = 0.5182 (t = -0.6528) p = 1.317e-13 (t = 9.439) p = 0.000005242 (t = 4.705) p = 0.1029 (t = 1.705)
ISOPCT αßγ-TERT ISOPCT αßγ-TERT ISOPCT αßγ-TERT ISOPCT αßγ-TERT ISOPCT αßγ-TERT ISOPCT αßγ-TERT ISOPCT αßγ-TERT ISOPCT αßγ-TERT
p = 0.6184 (t = 0.5020) p = 0.1554 (t = 1.442) p = 0.005279 (t = -2.811) p = NaN (t = NaN) p = NaN (t = NaN) p = 0.2838 (t = 1.086) p = 0.6636 (t = 0.4355) p = NaN (t = NaN)
ISOPCT γ-TERT ISOPCT γ-TERT ISOPCT γ-TERT ISOPCT γ-TERT ISOPCT γ-TERT ISOPCT γ-TERT ISOPCT γ-TERT ISOPCT γ-TERT
p = 0.04175 (t = 2.102) p = 0.7323 (t = -0.3427) p = 0.003150 (t = -2.978) p = NaN (t = NaN) p = NaN (t = NaN) p = 0.2479 (t = 1.171) p = 0.5872 (t = 0.5437) p = NaN (t = NaN)
ISOPCT ß-TERT ISOPCT ß-TERT ISOPCT ß-TERT ISOPCT ß-TERT ISOPCT ß-TERT ISOPCT ß-TERT ISOPCT ß-TERT ISOPCT ß-TERT
p = 0.04099 (t = 2.110) p = 0.1981 (t = 1.298) p = 0.1310 (t = 1.518) p = 0.7731 (t = -0.2890) p = 0.6036 (t = -0.5240) p = 0.2983 (t = 1.052) p = 0.6430 (t = -0.4640) p = NaN (t = NaN)
ISOPCT TERT_238.6 ISOPCT TERT_238.6 ISOPCT TERT_238.6 ISOPCT TERT_238.6 ISOPCT TERT_238.6 ISOPCT TERT_238.6 ISOPCT TERT_238.6 ISOPCT TERT_238.6
p = 0.009218 (t = -2.703) p = 0.1514 (t = -1.444) p = 0.02090 (t = -2.327) p = 0.5952 (t = 0.5332) p = 0.05055 (t = -2.032) p = 0.002547 (t = 3.143) p = 0.01162 (t = 2.544) p = 0.04793 (t = 2.095)
ISOPCT TERT_656.1 ISOPCT TERT_656.1 ISOPCT TERT_656.1 ISOPCT TERT_656.1 ISOPCT TERT_656.1 ISOPCT TERT_656.1 ISOPCT TERT_656.1 ISOPCT TERT_656.1
p = 0.8586 (t = -0.1791) p = 0.3047 (t = 1.035) p = 0.004766 (t = -2.840) p = 0.1565 (t = -1.427) p = 0.6081 (t = -0.5178) p = 0.8852 (t = -0.1451) p = 0.01577 (t = 2.438) p = 0.3178 (t = 1.027)
EXP TERT_877.1 EXP TERT_877.1 EXP TERT_877.1 EXP TERT_877.1 EXP TERT_877.1 EXP TERT_877.1 EXP TERT_877.1 EXP TERT_877.1
p = 0.6944 (t = 0.3952) p = 0.3173 (t = -1.005) p = 0.1577 (t = -1.417) p = 1.205e-12 (t = -9.199) p = 0.000 (t = 12.53) p = 0.7593 (t = -0.3078) p = 0.3173 (t = -1.003) p = 0.0003784 (t = -4.359)
EXP FL-TERT EXP FL-TERT EXP FL-TERT EXP FL-TERT EXP FL-TERT EXP FL-TERT EXP FL-TERT EXP FL-TERT
p = 0.4073 (t = -0.8351) p = 0.9579 (t = -0.05295) p = 0.8042 (t = 0.2482) p = 0.1582 (t = 1.433) p = 0.4190 (t = -0.8184) p = 7.333e-10 (t = 7.044) p = 0.00003555 (t = 4.238) p = 0.03937 (t = 2.172)
EXP αßγ-TERT EXP αßγ-TERT EXP αßγ-TERT EXP αßγ-TERT EXP αßγ-TERT EXP αßγ-TERT EXP αßγ-TERT EXP αßγ-TERT
p = 0.5989 (t = 0.5301) p = 0.1583 (t = 1.432) p = 0.005427 (t = -2.802) p = 1.205e-12 (t = -9.199) p = 0.000 (t = 12.53) p = 0.4131 (t = 0.8261) p = 0.5150 (t = 0.6523) p = 0.0003784 (t = -4.359)
EXP γ-TERT EXP γ-TERT EXP γ-TERT EXP γ-TERT EXP γ-TERT EXP γ-TERT EXP γ-TERT EXP γ-TERT
p = 0.05837 (t = 1.947) p = 0.7671 (t = -0.2967) p = 0.002986 (t = -2.995) p = 1.205e-12 (t = -9.199) p = 0.000 (t = 12.53) p = 0.1582 (t = 1.437) p = 0.5775 (t = 0.5579) p = 0.0003784 (t = -4.359)
EXP ß-TERT EXP ß-TERT EXP ß-TERT EXP ß-TERT EXP ß-TERT EXP ß-TERT EXP ß-TERT EXP ß-TERT
p = 0.1426 (t = 1.493) p = 0.5391 (t = 0.6163) p = 0.4135 (t = 0.8195) p = 0.8281 (t = -0.2177) p = 0.4726 (t = -0.7269) p = 0.4510 (t = 0.7598) p = 0.7303 (t = -0.3451) p = 0.0003784 (t = -4.359)
EXP TERT_238.6 EXP TERT_238.6 EXP TERT_238.6 EXP TERT_238.6 EXP TERT_238.6 EXP TERT_238.6 EXP TERT_238.6 EXP TERT_238.6
p = 0.00002925 (t = -4.481) p = 0.04154 (t = -2.058) p = 0.00005787 (t = -4.082) p = 0.8263 (t = 0.2200) p = 0.04053 (t = -2.140) p = 0.04080 (t = 2.085) p = 0.08124 (t = 1.751) p = 0.04652 (t = 2.092)
EXP TERT_656.1 EXP TERT_656.1 EXP TERT_656.1 EXP TERT_656.1 EXP TERT_656.1 EXP TERT_656.1 EXP TERT_656.1 EXP TERT_656.1
p = 0.3829 (t = -0.8788) p = 0.3448 (t = 0.9513) p = 0.004755 (t = -2.840) p = 0.1564 (t = -1.427) p = 0.6084 (t = -0.5172) p = 0.5068 (t = -0.6682) p = 0.02350 (t = 2.284) p = 0.3178 (t = 1.027)
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B.2.  Ensembl annotations of TERT isoforms used in Toil recomputed dataset 
 (Build  93) and CCLE dataset (Build 75). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1                                           2                                      3        4        5      6      7   8      9   10    11   12  13    14     15                 16 
Transcript ID
Abbreviation
bp Protein
ENST00000296820.5 TERT_820.5 (ß-TERT) 3829 807aa
1132aa
1069aa
807aa
795aa
No Protein
No protein
No protein
TERT_581.9 (FL-TERT)
TERT_602.10 (γ-TERT)
TERT_104.2 (ß-TERT)
TERT_137.6 (αßγ-TERT)
TERT_877.1
TERT_238.6
TERT_656.1
ENST00000484238.6
ENST00000503656.1
2486
4018
3210
2992
408
2422
406
ENST00000310581.9
ENST00000334602.10
ENST00000508104.2
ENST00000460137.6
ENST00000522877.1
Ensembl Build 75
GRCh37.p13
Transcript ID Abbreviation bp Protein
ENST00000484238.6 TERT_238.6 2422 No protein
ENST00000503656.1 TERT_656.1 406 No protein
Ensembl Build 93
GRCh38.p12
ENST00000310581.9 TERT_581.9 (FL-TERT) 4018
ENST00000334602.10 TERT_602.10 (γ-TERT) 3210
ENST00000508104.2 TERT_104.2 (ß-TERT) 2486
ENST00000460137.6 TERT_137.6 (αßγ-TERT) 2992
ENST00000522877.1 TERT_877.1
795aa
408 No protein
1132aa
1069aa
807aa
   1                                           2                                      3        4        5      6      7   8      9   10    11   12  13    14     15                 16 TERT_104.2 (Ensembl Build 93) 
TERT_820.5 (Ensembl Build 75) 
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B.3.  Comparison of telomere length from Normal Peripheral Blood and Normal 
Adjacent Tissue for each TCGA tissue type 
 
 
Figure B.3. Telomere length data was taken from Barthel et al., 2017 to determine which 
matched normal telomere length estimate to use for normalizing tumour telomere estimates, 
due to significant relationships with clinical variables such as patient age. Using a 
Wilcoxon rank sum test we compared telomere length estimates from normal peripheral 
blood leukocyte (NB) with normal matched adjacent tissue (NT) for each tumour type. We 
found significantly (p < 0.05) longer telomere length estimates for NT measurements in 
bladder (BLCA), liver (LIHC), lung (LUSC) and stomach (STAD) cancers.  
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Appendix C: Telomere Length and Telomerase Activity Signature Score 
 
C.1.  Telomere Length Data 
Telomere length (TL) was quantified using TelSeq (Ding et al., 2014). This tool 
counted the number of reads containing telomeric repeats, set at a minimum of seven 
repeats. Using this read count, as well as adjusting for GC-coverage, an estimated 
telomere length in kilobase pairs is determined when multiplied with the average 
chromosome length. This computation was done individually for each read group within a 
sample and subsequently weight-averaged for each sample. Telomere lengths were 
computed for TCGA tumour samples and either matched normal tissue (NT) or matched 
normal blood (NB) samples. Since, telomere length displayed a significant negative 
correlation with patient age (Barthel et al., 2017), normalizing within each patient was 
crucial. Tumour TL was divided by matched normal TL to generate a TL ratio. These TL 
ratio values were taken from Barthel et al. 
 
C.2.  Telomerase Activity Signature Score Genes 
CECR1, RRAS2, RARRES2, CTSC, LCK, RAD51AP1, ANOS1, FKBP5, 
GABRB3, IFITM1, ST6GAL1, PIM2, LYPLA1, SORL1, ALPL, NLGN4X, SLC39A10, 
COCH, TMX1, GLDC, AKIRIN1, DHFR, PARP1, PASK, POLE2, TRIM22, PRMT3, 
PDCD2, PAICS, C1QBP, KCNS3, DSCC1, NFE2L3, FRAT2, ECT2, CCNB1, 
THEMIS2, MIS18BP1, NUP107, LRRN1, DSG2, HMMR, CDC20 
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Appendix D: Survival Analysis 
 
D.1. Univariate overall survival (OS) Cox regressions  
 
 
 
 
Table D.1. Univariate Cox regressions for overall survival. ß-values and hazard ratios 
in brackets; green colour indicates reduced survival with increased variable magnitude 
while red colour indicates improved survival with increased variable magnitude. Gender 
was labelled 1 for male, 2 for female. Yellow colour in cancer type abbreviation row names 
indicates using caution for any significant results. 
Age Gender Stage Grade Subtype
ACC 0.81 (2.2) p < 0.05
BLCA 0.032 (1) 0.510 (1.7) p < 0.05
CESC p < 0.05
CHOL
COAD 0.680 (2)
ESCA 1.00 (2.9) 0.87 (2.4)   
GBM 0.028 (1)       
HNSC 0.025 (1)           0.220 (1.3)     p < 0.05
KIRC 0.036 (1)            0.620 (1.9)         0.660 (1.9)          p < 0.05
KIRP -0.034 (0.97)    1.400 (4.2)    
LAML 0.04 (1)
LIHC 0.36 (1.4)     
LUAD 0.500 (1.7)   
LUSC
MESO
OV 0.025 (1)      
PAAD p < 0.05
SARC
SKCM 1.10 (2.9)     
STAD 0.023 (1)            0.490 (1.6)        
UCEC 0.99 (2.7)      p < 0.05
UCS 0.056 (1.1)       0.460 (1.6)      p < 0.05
UVM 0.041 (1)       1.200 (3.3)      
BRCA 0.038 (1)        0.760 (2.1)     
KICH 2 (7.1)     
LGG 0.078 (1.1)     1.500 (4.5)   p < 0.05
PRAD
READ 0.11 (1.1)
THCA 0.082 (1.1)        1.300 (3.6)     
FL-TERT
(exp)
FL-TERT
(isopct)
TERT_238.6
(exp)
TERT_238.6
(isopct)
TERT_656.1
(exp)
TERT_656.1
(isopct)
ß-TERT
(exp)
ß-TERT
(isopct)
αßγ-TERT 
(exp)
αßγ-TERT 
(isopct)
γ-TERT 
(exp)
γ-TERT 
(isopct)
TERT_877.1
(exp)
TERT_877.1
(isopct)
Total TERT
ACC
BLCA
CESC
CHOL 0.14 (1.1)
COAD 0.200 (1.2) 0.120 (1.1)      0.089 (1.1)   0.280 (1.3)    
ESCA -0.17 (0.84) 0.18 (1.2) 0.22 (1.2)  0.10 (1.1)      0.14 (1.2)    0.14 (1.2)    0.22 (1.2)   0.23 (1.3)     
GBM 0.130 (1.1)     
HNSC -0.100 (0.9)  
KIRC 0.062 (1.1)           -0.270 (0.76)       
KIRP 0.270 (1.3)      0.310 (1.4)   
LAML
LIHC
LUAD 0.064 (1.1)   0.120 (1.1)      
LUSC -0.11 (0.9)      0.16 (1.2)     
MESO 0.120 (1.1)       0.097 (1.1)        0.085 (1.1)      0.240 (1.3)  0.220 (1.2)     0.210 (1.2)   
OV
PAAD
SARC 0.098 (1.1)     0.100 (1.1)       0.170 (1.2)        0.130 (1.1)      
SKCM 0.32 (1.4)        
STAD -0.074 (0.93)     -0.140 (0.87)  
UCEC
UCS -0.270 (0.76)
UVM
BRCA 0.074 (1.1)      
KICH
LGG 0.088 (1.1)     0.100 (1.1)       0.140 (1.1)      
PRAD 0.54 (1.7)        
READ -0.46 (0.63)  
THCA 0.290 (1.3)      0.390 (1.5)        0.330 (1.4)     
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D.2. Univariate progression-free interval Cox regressions  
 
 
 
 
Table D.2. Univariate Cox regressions for progression free interval. ß-values and 
hazard ratios in brackets; green colour indicates poorer progression-free interval with 
increased variable magnitude while red colour indicates improved progression-free interval 
with increased variable magnitude. Gender was labelled 1 for male, 2 for female. Yellow 
colour in cancer type abbreviation row names indicates using caution for any significant 
results. 
Age Gender Stage Grade Subtype
ACC 0.49 (1.6) p < 0.05
BLCA 0.57 (1.8) p < 0.05
BRCA 0.89 (2.4) p < 0.05
CESC 0.59 (1.8)
CHOL
COAD 0.750 (2.1)
ESCA 1.10 (2.9)
GBM
HNSC 0.28 (1.3)
KIRC 1.00 (2.8) 0.91 (2.5) p < 0.05
KIRP 0.87 (2.4) 1.20 (3.2) p < 0.05
LGG 0.044 (1) 0.850 (2.3) p < 0.05
LIHC -0.020 (0.98) 0.500 (1.7) 0.320 (1.4)
LUAD 0.240 (1.3) p < 0.05
LUSC -0.88 (0.42) 
MESO
OV p < 0.05
PAAD p < 0.05
PRAD
READ 1.20 (3.2)
SARC
SKCM -0.032 (0.97) 0.960 (2.6)
STAD -0.680 (0.51) 0.380 (1.5)
TGCT -0.99 (0.37) p < 0.05
THCA 0.55 (1.7) p < 0.05
THYM
UCEC 0.64 (1.9) p < 0.05
UCS 0.042 (1) 0.360 (1.4) p < 0.05
UVM 0.870 (2.4) p < 0.05
DLBC
KICH 1.7 (5.7)
FL-TERT
(exp)
FL-TERT
(isopct)
TERT_238.6
(exp)
TERT_238.6
(isopct)
TERT_656.1
(exp)
TERT_656.1
(isopct)
ß-TERT
(exp)
ß-TERT
(isopct)
αßγ-TERT 
(exp)
αßγ-TERT 
(isopct)
γ-TERT 
(exp)
γ-TERT 
(isopct)
TERT_877.1
(exp)
TERT_877.1
(isopct)
Total TERT
ACC
BLCA
BRCA
CESC
CHOL
COAD 0.076 (1.1) 0.091 (1.1)
ESCA 0.10 (1.1) 0.18 (1.2)
GBM
HNSC
KIRC 0.23 (1.3) 0.20 (1.2)
KIRP 0.26 (1.3) 0.16 (1.2) 0.19 (1.2) 0.28 (1.3)
LGG 0.054 (1.1)
LIHC 0.140 (1.1)
LUAD 0.061 (1.1)
LUSC
MESO 0.34 (1.4) 0.20 (1.2)
OV -0.17 (0.84) -0.18 (0.84)
PAAD
PRAD
READ 0.78 (2.2) 2.10 (8.2)
SARC 0.081 (1.1) 0.140 (1.2) 0.230 (1.3)
SKCM
STAD 0.100 (1.1) -0.099 (0.91) -0.190 (0.83)
TGCT 0.13 (1.1)
THCA 0.18 (1.2) -0.20 (0.82) 0.34 (1.4) 0.33 (1.4)
THYM -0.3 (0.74)
UCEC -0.22 (0.81)
UCS
UVM
DLBC
KICH
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Appendix E: Supplemental Analyses  
 
E.1.  ß-TERT isoform percentage correlation to telomere length ratio  
 
 
 
Figure E.1. Telomere length ratios and ß-TERT isoform percentage were log10 and 
log2(Isoform Percentage + 1) transformed, respectively. Scatter plots were fitted with a 
linear regression line and 95% confidence interval. Spearman’s correlation coefficient and 
uncorrected p-value are displayed within each scatter plot. Correlations significant after 
Bonferroni correction (p < 0.05) are highlighted with a red border 
R = -0.016, p = 0.91
R = -0.18, p = 0.24
R = 0.22, p = 0.046
R = -0.057, p = 0.54
R = 0.064, p = 0.23
R = -0.011, p = 0.93
R = -0.054, p = 0.3
R = -0.26, p = 0.0049
R = -0.033, p = 0.56
R = , 
R = 0.013, p = 0.88
R = 0.053, p = 0.15
R = 0.11, p = 0.21
R = 0.018, p = 0.76
R = 0.022, p = 0.66
R = 0.019, p = 0.83
R = 0.017, p = 0.87
R = 0.067, p = 0.15
R = -0.013, p = 0.79
R = -0.052, p = 0.65
R = 0.089, p = 0.36
R = -0.0073, p = 0.97
R = , 
R = -0.11, p = 0.062
R = 0.022, p = 0.83
R = -0.41, p = 0.19
R = 0.012, p = 0.84
R = 0.045, p = 0.74
R = -0.24, p = 0.11
R = 0.17, p = 0.098
R = 0.11, p = 0.46
TCGA UVM
TCGA STAD TCGA TGCT TCGA THCA TCGA THYM TCGA UCEC TCGA UCS
TCGA PAAD TCGA PCPG TCGA PRAD TCGA READ TCGA SARC TCGA SKCM
TCGA KIRP TCGA LGG TCGA LIHC TCGA LUAD TCGA LUSC TCGA OV
TCGA DLBC TCGA ESCA TCGA GBM TCGA HNSC TCGA KICH TCGA KIRC
TCGA ACC TCGA BLCA TCGA BRCA TCGA CESC TCGA CHOL TCGA COAD
−1.5−1.0−0.5 0.0
−5.0−2.5 0.0 2.5 5.0−1 0 1 2 −2 0 2 −2 −1 0 1−1.0−0.50.0 0.5 1.0−5.0−2.5 0.0 2.5
−2.5 0.0 2.5 −1.0 −0.5 0.0 0.5 −4 −2 0 2 −1 0 1 2−2.5 0.0 2.5 −3 −2 −1 0 1
−2 −1 0 1 2 3 −2 0 2 4 −2 −1 0 1 2 −5.0−2.50.0 2.5 5.0 −4 −2 0 2 −1 0 1
−1.0−0.50.0 0.5 −4 −2 0 2 −5.0−2.5 0.0 2.5 −2.5 0.0 2.5 −0.5 −0.4 −0.3−4 −2 0 2
−3−2−1 0 1 2 −2 0 2 −2 0 2 −4 −2 0 2 −2 −1 0 1 −2 0 2
−2
0
2
−2
0
2
−2
0
2
−2
0
2
−2
0
2
−2
0
2
log(Tumour TL/Control TL)
TE
RT
_1
04
.2
 [l
og
2(
Is
of
or
m
 P
er
ce
nt
ag
e 
+ 
1)
]
 130 
E.2.  ß-TERT expression correlation to telomere length ratio  
 
 
 
Figure E.2. Telomere length ratios and ß-TERT expression were log10 and log2(TPM + 
0.001) transformed, respectively. Scatter plots were fitted with a linear regression line and 
95% confidence interval. Spearman’s correlation coefficient and uncorrected p-value are 
displayed within each scatter plot. Correlations significant after Bonferroni correction (p < 
0.05) are highlighted with a red border 
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E.3.  αßγ-TERT isoform percentage correlation to telomere length ratio  
 
 
 
Figure E.3. Telomere length ratios and αßγ-TERT isoform percentage were log10 and 
log2(Isoform Percentage + 1) transformed, respectively. Scatter plots were fitted with a 
linear regression line and 95% confidence interval. Spearman’s correlation coefficient and 
uncorrected p-value are displayed within each scatter plot. Correlations significant after 
Bonferroni correction (p < 0.05) are highlighted with a red border 
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E.4.  αßγ-TERT expression correlation to telomere length ratio  
 
 
 
Figure E.4. Telomere length ratios and αßγ-TERT expression were log10 and log2(TPM + 
0.001) transformed, respectively. Scatter plots were fitted with a linear regression line and 
95% confidence interval. Spearman’s correlation coefficient and uncorrected p-value are 
displayed within each scatter plot. Correlations significant after Bonferroni correction (p < 
0.05) are highlighted with a red border 
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E.5.  γ-TERT isoform percentage correlation to telomere length ratio  
 
 
 
Figure E.5. Telomere length ratios and γ-TERT isoform percentage were log10 and 
log2(Isoform Percentage + 1) transformed, respectively. Scatter plots were fitted with a 
linear regression line and 95% confidence interval. Spearman’s correlation coefficient and 
uncorrected p-value are displayed within each scatter plot. Correlations significant after 
Bonferroni correction (p < 0.05) are highlighted with a red border 
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E.6.  γ-TERT expression correlation to telomere length ratio  
 
 
 
Figure E.6. Telomere length ratios and γ-TERT expression were log10 and log2(TPM + 
0.001) transformed, respectively. Scatter plots were fitted with a linear regression line and 
95% confidence interval. Spearman’s correlation coefficient and uncorrected p-value are 
displayed within each scatter plot. Correlations significant after Bonferroni correction (p < 
0.05) are highlighted with a red border 
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E.7. TERT_656.1 isoform percentage correlation to telomere length ratio  
 
 
 
Figure E.7. Telomere length ratios and TERT_656.1 isoform percentage were log10 and 
log2(Isoform Percentage + 1) transformed, respectively. Scatter plots were fitted with a 
linear regression line and 95% confidence interval. Spearman’s correlation coefficient and 
uncorrected p-value are displayed within each scatter plot. Correlations significant after 
Bonferroni correction (p < 0.05) are highlighted with a red border 
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E.8. TERT_656.1 expression correlation to telomere length ratio  
 
 
 
Figure E.8. Telomere length ratios and TERT_656.1 expression were log10 and log2(TPM 
+ 0.001) transformed, respectively. Scatter plots were fitted with a linear regression line 
and 95% confidence interval. Spearman’s correlation coefficient and uncorrected p-value 
are displayed within each scatter plot. Correlations significant after Bonferroni correction 
(p < 0.05) are highlighted with a red border 
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E.9. TERT_877.1 isoform percentage correlation to telomere length ratio  
 
 
 
Figure E.9. Telomere length ratios and TERT_877.1 isoform percentage were log10 and 
log2(Isoform Percentage + 1) transformed, respectively. Scatter plots were fitted with a 
linear regression line and 95% confidence interval. Spearman’s correlation coefficient and 
uncorrected p-value are displayed within each scatter plot. Correlations significant after 
Bonferroni correction (p < 0.05) are highlighted with a red border 
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E.10 TERT_877.1 expression correlation to telomere length ratio  
 
 
 
Figure E.10. Telomere length ratios and TERT_877.1 expression were log10 and log2(TPM 
+ 0.001) transformed, respectively. Scatter plots were fitted with a linear regression line 
and 95% confidence interval. Spearman’s correlation coefficient and uncorrected p-value 
are displayed within each scatter plot. Correlations significant after Bonferroni correction 
(p < 0.05) are highlighted with a red border 
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E.11. Comparing expression of negative ALT regulators between TERT-positive and 
 TERT-negative solid TCGA tumour samples 
 
 
Figure E.11. TCGA primary solid tumours (haematological tumours removed) were 
stratified into TERT-positive (+) and TERT-negative (-) if TERT expression was greater 
than zero transcripts per million. The expression of various negative regulators of ALT, 
(outlined by Zhang & Zou, 2020), were compared between both subgroups by Welch’s t-
test on the UCSC Xena Platform after loading the Toil Recompute Dataset.   
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E.12. Testicular Germ Cell Tumour (TGCT) Subtypes FL-TERT Expression Differences  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure E.15. Using a Wilcoxon rank sum test between TGCT subtypes to identify 
significant differences (Bonferroni corrected p-value < 0.05) for FL-TERT expression. 
Significant differences were highlighted in red.  
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Appendix F: Cancer Cell Line Encyclopedia UMAP Projections  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure F.1. UMAP projection of biliary tract CCLE cell lines and TCGA 
Cholangiocarcinoma (CHOL) using TERT isoform expression. Cell lines HUCCT1 and 
SNU869 were closest to average isoform percentage from CHOL tumours. Dashed-line 
box indicates a zoomed in region of interest with text labels of cell lines. Cell line TERT 
promoter status taken from Ghandi et al., 2019. Superscript “P” indicated TERT promoter 
mutation, superscript “WT” indicates wild-type TERT promoter and no superscript 
indicates no data available. Parameters: Manhattan distance, 2 neighbours and 3 
components.  
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Figure F.2. UMAP projection of haematopoietic and lymphoid tissue CCLE cell lines, 
TCGA lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), TCGA acute 
myeloid leukemia (LAML) and GTEx whole blood using TERT isoform expression. 
Cell line OCIAML5 was closest to average isoform percentage from TCGA LAML. Cell 
lines SUPM2, KMH2, HL60, RS411 and LOUCY were closest to average isoform 
percentage from TCGA DLBC and GTEx blood. Cell line TERT promoter status taken 
from Ghandi et al., 2019. Superscript “P” indicated TERT promoter mutation, superscript 
“WT” indicates wild-type TERT promoter and no superscript indicates no data available. 
Dashed-line box indicates a zoomed in region of interest with text labels of cell lines. 
Parameters: Manhattan distance, 16 neighbours and 4 components.  
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Figure F.3. UMAP projection of central nervous system and autonomic ganglia CCLE 
cell lines, TCGA brain lower grade glioma (LGG), TCGA glioblastoma multiforme 
(GBM) and GTEx brain cortex using TERT isoform expression. Cell line IOMMLEE 
was closest to average isoform percentage from TCGA LGG and GBM. Cell lines TM31, 
LNZ308 and DKMG were closest to average isoform percentage from TCGA PCPG and 
GTEx brain. Cell line TERT promoter status taken from Ghandi et al., 2019. Superscript 
“P” indicated TERT promoter mutation, superscript “WT” indicates wild-type TERT 
promoter and no superscript indicates no data available. Dashed-line box indicates a 
zoomed in region of interest with text labels of cell lines. Parameters: Manhattan distance, 
8 neighbours and 4 components.  
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Figure F.4. UMAP projection of breast CCLE cell lines, TCGA breast invasive 
carcinoma (BRCA) and GTEx breast using TERT isoform expression. Cell lines 
JIMT1 and BT549 were closest to average isoform percentage from TCGA BRCA. Cell 
line MDAMB231 was closest to average isoform percentage from GTEx breast. Cell line 
TERT promoter status taken from Ghandi et al., 2019. Superscript “P” indicated TERT 
promoter mutation, superscript “WT” indicates wild-type TERT promoter and no 
superscript indicates no data available. Dashed-line box indicates a zoomed in region of 
interest with text labels of cell lines. Parameters: Manhattan distance, 8 neighbours and 4 
components.  
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Figure F.5. UMAP projection of large intestine CCLE cell lines, TCGA colon 
adenocarcinoma (COAD) and GTEx colon using TERT isoform expression. Cell line 
CL11 was closest to average isoform percentage from TCGA COAD, accompanied by cell 
lines CW2 and SNU1197. Cell line LS1034 was closest to average isoform percentage from 
GTEx colon. Cell line TERT promoter status taken from Ghandi et al., 2019. Superscript 
“P” indicated TERT promoter mutation, superscript “WT” indicates wild-type TERT 
promoter and no superscript indicates no data available. Dashed-line box indicates a 
zoomed in region of interest with text labels of cell lines. Parameters: Manhattan distance, 
8 neighbours and 4 components.  
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Figure F.6. UMAP projection of endometrium CCLE cell lines, TCGA uterine corpus 
endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS) and cervical 
squamous cell carcinoma (CESC), and GTEx uterus and cervix using TERT isoform 
expression. Cell line JHUEM7 was closest to average isoform percentage from GTEx 
tissues. Cell line JHUEM2 was closest to average isoform percentage from TCGA tissues. 
TCGA UCEC was also close to JHUEM7. Cell line TERT promoter status taken from 
Ghandi et al., 2019. Superscript “P” indicated TERT promoter mutation, superscript “WT” 
indicates wild-type TERT promoter and no superscript indicates no data available. Dashed-
line box indicates a zoomed in region of interest with text labels of cell lines. Parameters: 
Manhattan distance, 4 neighbours and 4 components.  
 
 
 
 
 
 
JHUEM7 
JHUEM2 
 147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure F.7. UMAP projection of esophagus CCLE cell lines, TCGA esophageal 
carcinoma (ESCA) and GTEx esophagus using TERT isoform expression. Cell lines 
TE11, KYSE510, KYSE410 and COLO680N were closest to average isoform percentage 
from TCGA ESCA and GTEx esophagus. Cell line TERT promoter status taken from 
Ghandi et al., 2019. Superscript “P” indicated TERT promoter mutation, superscript “WT” 
indicates wild-type TERT promoter and no superscript indicates no data available. Dashed-
line box indicates a zoomed in region of interest with text labels of cell lines. Parameters: 
Manhattan distance, 4 neighbours and 4 components.  
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Figure F.8. UMAP projection of kidney CCLE cell lines, TCGA kidney chromophobe 
(KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell 
carcinoma (KIRP) and GTEx kidney using TERT isoform expression. Cell line 
CAKI1was closest to average isoform percentage from tumour and normal kidney tissues. 
Cell line TERT promoter status taken from Ghandi et al., 2019. Superscript “P” indicated 
TERT promoter mutation, superscript “WT” indicates wild-type TERT promoter and no 
superscript indicates no data available. Dashed-line box indicates a zoomed in region of 
interest with text labels of cell lines. Parameters: Manhattan distance, 4 neighbours and 4 
components.  
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Figure F.9. UMAP projection of liver CCLE cell lines, TCGA liver hepatocellular 
carcinoma (LIHC) and GTEx liver using TERT isoform expression. Cell lines HEPG2 
and LI7 were closest to average isoform percentage from TCGA LIHC. Cell lines SNU878 
and JHH1 were closest to average isoform percentage from GTEx liver. Cell line TERT 
promoter status taken from Ghandi et al., 2019. Superscript “P” indicated TERT promoter 
mutation, superscript “WT” indicates wild-type TERT promoter and no superscript 
indicates no data available. Dashed-line box indicates a zoomed in region of interest with 
text labels of cell lines. Parameters: Manhattan distance, 4 neighbours and 4 components.  
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Figure F.10. UMAP projection of lung CCLE cell lines, TCGA lung adenocarcinoma 
(LUAD), TCGA lung squamous cell carcinoma (LUSC) and GTEx lung using TERT 
isoform expression. Cell lines NCIH596, NCIH2228, NCIH1755 and CORL47 were 
closest to average isoform percentage from TCGA LUSC. Cell lines NCIH2030, DMS152, 
NCIH727 and MORCPR were closest to average isoform percentage from TCGA LUSC. 
Cell lines NCIH524, NCIH1836 and NCIH2066 were closest to average isoform 
percentage from GTEx lung. Cell line TERT promoter status taken from Ghandi et al., 
2019. Superscript “P” indicated TERT promoter mutation, superscript “WT” indicates 
wild-type TERT promoter and no superscript indicates no data available. Dashed-line box 
indicates a zoomed in region of interest with text labels of cell lines. Parameters: Manhattan 
distance, 16 neighbours and 4 components.  
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Figure F.11. UMAP projection of ovarian CCLE cell lines, TCGA ovarian serous 
cystadenocarcinoma (OV) and GTEx ovary using TERT isoform expression. Cell lines 
COV362, JHOM1, TOV112D and OVK18 were closest to average isoform percentage 
from TCGA OV. Cell lines OVKATE, OV90 and HEYA8 were closest to average isoform 
percentage from GTEx ovary. Cell line TERT promoter status taken from Ghandi et al., 
2019. Superscript “P” indicated TERT promoter mutation, superscript “WT” indicates 
wild-type TERT promoter and no superscript indicates no data available. Dashed-line box 
indicates a zoomed in region of interest with text labels of cell lines. Parameters: Manhattan 
distance, 8 neighbours and 4 components.  
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Figure F.12. UMAP projection of pancreas CCLE cell lines, TCGA pancreatic 
adenocarcinoma (PAAD) and GTEx pancreas using TERT isoform expression. Cell 
line CAPAN1 was closest to average isoform percentage from TCGA PAAD. Cell lines 
PANC1005, MIAPACA2 and CFPAC1 were closest to average isoform percentage from 
GTEx pancreas. Cell line TERT promoter status taken from Ghandi et al., 2019. 
Superscript “P” indicated TERT promoter mutation, superscript “WT” indicates wild-type 
TERT promoter and no superscript indicates no data available. Dashed-line box indicates 
a zoomed in region of interest with text labels of cell lines. Parameters: Manhattan distance, 
8 neighbours and 4 components.  
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Figure F.13. UMAP projection of pleura CCLE cell lines and TCGA mesothelioma 
(MESO) using TERT isoform expression. Cell lines NCIH2052 and ISTMES2 were 
closest to average isoform percentage from TCGA MESO. Cell line TERT promoter status 
taken from Ghandi et al., 2019. Superscript “P” indicated TERT promoter mutation, 
superscript “WT” indicates wild-type TERT promoter and no superscript indicates no data 
available. Dashed-line box indicates a zoomed in region of interest with text labels of cell 
lines. Parameters: Manhattan distance, 2 neighbours and 3 components.  
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Figure F.14. UMAP projection of prostate CCLE cell lines and TCGA prostate 
adenocarcinoma (PRAD) using TERT isoform expression. Cell line PC3 was closest to 
average isoform percentage from tumour and normal prostate tissues. Cell line TERT 
promoter status taken from Ghandi et al., 2019. Superscript “P” indicated TERT promoter 
mutation, superscript “WT” indicates wild-type TERT promoter and no superscript 
indicates no data available. Dashed-line box indicates a zoomed in region of interest with 
text labels of cell lines. Parameters: Manhattan distance, 2 neighbours and 3 components.  
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Figure F.15. UMAP projection of skin CCLE cell lines, TCGA skin cutaneous 
melanoma (SKCM) and GTEx skin using TERT isoform expression. Cell lines 
SKMEL1, SKMEL28, HT144 and HS695T were closest to average isoform percentage 
from tumour and normal skin tissues. Cell line TERT promoter status taken from Ghandi 
et al., 2019. Superscript “P” indicated TERT promoter mutation, superscript “WT” 
indicates wild-type TERT promoter and no superscript indicates no data available. Dashed-
line box indicates a zoomed in region of interest with text labels of cell lines. Parameters: 
Manhattan distance, 8 neighbours and 4 components.  
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Figure F.16. UMAP projection of soft tissue and bone CCLE cell lines, TCGA uterine 
carcinosarcoma (UCS) and TCGA sarcoma (SARC) using TERT isoform expression. 
Bone cell lines EW8 and CADOES1 and soft-tissue cell line RD were closest to average 
isoform percentage from TCGA UCS and SARC. Cell line TERT promoter status taken 
from Ghandi et al., 2019. Superscript “P” indicated TERT promoter mutation, superscript 
“WT” indicates wild-type TERT promoter and no superscript indicates no data available. 
Dashed-line box indicates a zoomed in region of interest with text labels of cell lines. 
Parameters: Manhattan distance, 8 neighbours and 4 components.  
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Figure F.17. UMAP projection of stomach CCLE cell lines, TCGA stomach 
adenocarcinoma (STAD) and GTEx stomach using TERT isoform expression. Cell 
lines MKN7, IM95 and OCUM1 were closest to average isoform percentage from TCGA 
STAD. Cell lines SNU216 and FU97 were closest to average isoform percentage from 
GTEx stomach. Cell line TERT promoter status taken from Ghandi et al., 2019. Superscript 
“P” indicated TERT promoter mutation, superscript “WT” indicates wild-type TERT 
promoter and no superscript indicates no data available. Dashed-line box indicates a 
zoomed in region of interest with text labels of cell lines. Parameters: Manhattan distance, 
8 neighbours and 4 components.  
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Figure F.18. UMAP projection of thyroid CCLE cell lines, TCGA thyroid carcinoma 
(THCA) and GTEx thyroid using TERT isoform expression. Cell line TT2609C02 was 
closest to average isoform percentage from tumour and normal thyroid tissues. Cell line 
TERT promoter status taken from Ghandi et al., 2019. Superscript “P” indicated TERT 
promoter mutation, superscript “WT” indicates wild-type TERT promoter and no 
superscript indicates no data available. Dashed-line box indicates a zoomed in region of 
interest with text labels of cell lines. Parameters: Manhattan distance, 2 neighbours and 3 
components.  
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Figure F.19. UMAP projection of urinary tract CCLE cell lines, TCGA bladder 
urothelial carcinoma (BLCA) and GTEx bladder using TERT isoform expression. 
Cell lines UMUC2 and CAL29 were closest to average isoform percentage from TCGA 
BLCA. Cell lines RT4 and ULBC1 were closest to average isoform percentage from GTEx 
bladder. Cell line TERT promoter status taken from Ghandi et al., 2019. Superscript “P” 
indicated TERT promoter mutation, superscript “WT” indicates wild-type TERT promoter 
and no superscript indicates no data available. Dashed-line box indicates a zoomed in 
region of interest with text labels of cell lines. Parameters: Manhattan distance, 4 
neighbours and 4 components.  
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